guid	sentence1	label
DDI-MedLine.d119.s1.p0	@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986. 	DDI-false
DDI-MedLine.d119.s2.p0	It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s2.p1	It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s2.p2	It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s2.p3	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s2.p4	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s2.p5	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	DDI-false
DDI-MedLine.d119.s15.p0	@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability. 	DDI-mechanism
DDI-MedLine.d119.s16.p0	Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy. 	DDI-effect
DDI-MedLine.d119.s17.p0	Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin. 	DDI-false
DDI-MedLine.d119.s17.p1	Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$. 	DDI-false
DDI-MedLine.d119.s17.p2	Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$. 	DDI-false
DDI-MedLine.d119.s18.p0	Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p1	Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p2	Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p3	Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p4	Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p5	Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p6	Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p7	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p8	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	DDI-false
DDI-MedLine.d119.s18.p9	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	DDI-false
DDI-DrugBank.d369.s1.p0	These would include a variety of preparations which contain @DRUG$, @DRUG$, progestins, or glucocorticoids.	DDI-false
DDI-DrugBank.d369.s1.p1	These would include a variety of preparations which contain @DRUG$, estrogens, @DRUG$, or glucocorticoids.	DDI-false
DDI-DrugBank.d369.s1.p2	These would include a variety of preparations which contain @DRUG$, estrogens, progestins, or @DRUG$.	DDI-false
DDI-DrugBank.d369.s1.p3	These would include a variety of preparations which contain androgens, @DRUG$, @DRUG$, or glucocorticoids.	DDI-false
DDI-DrugBank.d369.s1.p4	These would include a variety of preparations which contain androgens, @DRUG$, progestins, or @DRUG$.	DDI-false
DDI-DrugBank.d369.s1.p5	These would include a variety of preparations which contain androgens, estrogens, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d369.s2.p0	The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by @DRUG$, and suppressed by oral contraceptives and digoxin.	DDI-false
DDI-DrugBank.d369.s2.p1	The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by levodopa, and suppressed by oral @DRUG$ and digoxin.	DDI-false
DDI-DrugBank.d369.s2.p2	The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by levodopa, and suppressed by oral contraceptives and @DRUG$.	DDI-false
DDI-DrugBank.d369.s2.p3	The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by @DRUG$, and suppressed by oral @DRUG$ and digoxin.	DDI-false
DDI-DrugBank.d369.s2.p4	The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by @DRUG$, and suppressed by oral contraceptives and @DRUG$.	DDI-false
DDI-DrugBank.d369.s2.p5	The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d369.s3.p0	The response to @DRUG$ may be blunted by @DRUG$ and dopamine antagonists which cause a rise in prolactin.	DDI-effect
DDI-DrugBank.d369.s3.p1	The response to @DRUG$ may be blunted by phenothiazines and @DRUG$ which cause a rise in prolactin.	DDI-effect
DDI-DrugBank.d369.s3.p2	The response to Factrel may be blunted by @DRUG$ and @DRUG$ which cause a rise in prolactin.	DDI-false
DDI-MedLine.d125.s0.p0	The mode of toxic action of the pesticide @DRUG$: the metabolism of @DRUG$ to (-)-erythro-fluorocitrate.  	DDI-false
DDI-MedLine.d125.s0.p1	The mode of toxic action of the pesticide @DRUG$: the metabolism of 1,3-difluoroacetone to @DRUG$.  	DDI-false
DDI-MedLine.d125.s0.p2	The mode of toxic action of the pesticide gliftor: the metabolism of @DRUG$ to @DRUG$.  	DDI-false
DDI-MedLine.d125.s1.p0	The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide @DRUG$ (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	DDI-false
DDI-MedLine.d125.s1.p1	The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide Gliftor (@DRUG$), was investigated in vivo and in vitro. 	DDI-false
DDI-MedLine.d125.s1.p2	The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide @DRUG$ (@DRUG$), was investigated in vivo and in vitro. 	DDI-false
DDI-MedLine.d125.s2.p0	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted @DRUG$ to @DRUG$ in vitro. 	DDI-false
DDI-MedLine.d125.s3.p0	Administration of @DRUG$ (100 mg kg(-1) body weight) to rats in vivo resulted in @DRUG$ synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 	DDI-false
DDI-MedLine.d125.s4.p0	Animals dosed with @DRUG$ did not display the 2-3 hour lag phase in either @DRUG$ synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	DDI-false
DDI-MedLine.d125.s4.p1	Animals dosed with @DRUG$ did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with @DRUG$. 	DDI-false
DDI-MedLine.d125.s4.p2	Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either @DRUG$ synthesis or in citrate and fluoride accumulation characteristic of animals dosed with @DRUG$. 	DDI-false
DDI-MedLine.d125.s5.p0	We demonstrate that the conversion of @DRUG$ to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	DDI-false
DDI-MedLine.d125.s5.p1	We demonstrate that the conversion of @DRUG$ to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from 1,3-difluoro-2-propanol. 	DDI-false
DDI-MedLine.d125.s5.p2	We demonstrate that the conversion of @DRUG$ to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from @DRUG$. 	DDI-false
DDI-MedLine.d125.s5.p3	We demonstrate that the conversion of 1,3-difluoro-2-propanol to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from 1,3-difluoro-2-propanol. 	DDI-false
DDI-MedLine.d125.s5.p4	We demonstrate that the conversion of 1,3-difluoro-2-propanol to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from @DRUG$. 	DDI-false
DDI-MedLine.d125.s5.p5	We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from @DRUG$. 	DDI-false
DDI-MedLine.d125.s6.p0	Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	DDI-effect
DDI-MedLine.d125.s6.p1	Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	DDI-false
DDI-MedLine.d125.s6.p2	Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	DDI-false
DDI-MedLine.d125.s6.p3	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	DDI-false
DDI-MedLine.d125.s6.p4	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	DDI-false
DDI-MedLine.d125.s6.p5	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	DDI-false
DDI-MedLine.d125.s7.p0	However, administration of @DRUG$ (90 mg kg(-1) body weight) to rats 2 hours prior to @DRUG$ (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	DDI-false
DDI-MedLine.d125.s7.p1	However, administration of @DRUG$ (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing @DRUG$ synthesis and did not diminish fluoride or citrate accumulation in vivo. 	DDI-false
DDI-MedLine.d125.s7.p2	However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to @DRUG$ (100 mg kg(-1) body weight) was ineffective in preventing @DRUG$ synthesis and did not diminish fluoride or citrate accumulation in vivo. 	DDI-false
DDI-MedLine.d125.s8.p0	We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	DDI-effect
DDI-MedLine.d125.s8.p1	We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to 1,3-difluoroacetone in the committed step of the toxic pathway.	DDI-false
DDI-MedLine.d125.s8.p2	We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to @DRUG$ in the committed step of the toxic pathway.	DDI-false
DDI-MedLine.d125.s8.p3	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to 1,3-difluoroacetone in the committed step of the toxic pathway.	DDI-false
DDI-MedLine.d125.s8.p4	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to @DRUG$ in the committed step of the toxic pathway.	DDI-false
DDI-MedLine.d125.s8.p5	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to @DRUG$ in the committed step of the toxic pathway.	DDI-false
DDI-MedLine.d86.s0.p0	Pharmacokinetic interaction between single oral doses of @DRUG$ and @DRUG$ in healthy volunteers.  	DDI-mechanism
DDI-MedLine.d86.s1.p0	AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a @DRUG$ metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s1.p1	AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a macrolide immunosuppressant metabolized by CYP3A4, and the @DRUG$ diltiazem was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s1.p2	AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker @DRUG$ was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s1.p3	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a @DRUG$ metabolized by CYP3A4, and the @DRUG$ diltiazem was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s1.p4	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a @DRUG$ metabolized by CYP3A4, and the calcium channel blocker @DRUG$ was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s1.p5	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the @DRUG$ @DRUG$ was studied in 18 healthy subjects. 	DDI-false
DDI-MedLine.d86.s2.p0	Several clinically important interactions have previously been reported for other @DRUG$ that are metabolized by the same enzyme and for @DRUG$. 	DDI-false
DDI-MedLine.d86.s3.p0	METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of @DRUG$, a single oral 120-mg dose of @DRUG$, and the two drugs given together. 	DDI-false
DDI-MedLine.d86.s5.p0	RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	DDI-mechanism
DDI-MedLine.d86.s5.p1	RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours. 	DDI-false
DDI-MedLine.d86.s5.p2	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours. 	DDI-false
DDI-MedLine.d86.s6.p0	Apparent oral clearance and volume of distribution of @DRUG$ decreased with 38% and 45%, respectively, when @DRUG$ was given with diltiazem. 	DDI-false
DDI-MedLine.d86.s6.p1	Apparent oral clearance and volume of distribution of @DRUG$ decreased with 38% and 45%, respectively, when sirolimus was given with @DRUG$. 	DDI-false
DDI-MedLine.d86.s6.p2	Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when @DRUG$ was given with @DRUG$. 	DDI-mechanism
DDI-MedLine.d86.s7.p0	The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p1	The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p2	The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p3	The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p4	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p5	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p6	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p7	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p8	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s7.p9	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	DDI-false
DDI-MedLine.d86.s8.p0	CONCLUSIONS: Single-dose @DRUG$ coadministration leads to higher @DRUG$ exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	DDI-mechanism
DDI-MedLine.d86.s8.p1	CONCLUSIONS: Single-dose @DRUG$ coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of @DRUG$. 	DDI-false
DDI-MedLine.d86.s8.p2	CONCLUSIONS: Single-dose diltiazem coadministration leads to higher @DRUG$ exposure, presumably by inhibition of the first-pass metabolism of @DRUG$. 	DDI-false
DDI-MedLine.d86.s9.p0	Because of the pronounced intersubject variability in the extent of the @DRUG$-@DRUG$ interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	DDI-advise
DDI-MedLine.d86.s9.p1	Because of the pronounced intersubject variability in the extent of the @DRUG$-diltiazem interaction, whole blood @DRUG$ concentrations should be monitored closely in patients treated with the two drugs.	DDI-false
DDI-MedLine.d86.s9.p2	Because of the pronounced intersubject variability in the extent of the sirolimus-@DRUG$ interaction, whole blood @DRUG$ concentrations should be monitored closely in patients treated with the two drugs.	DDI-false
DDI-DrugBank.d399.s0.p0	Preliminary data which suggest that @DRUG$ may inhibit the anti-inflammatory activity of @DRUG$ have not been confirmed.	DDI-effect
DDI-DrugBank.d399.s1.p0	If leprosy-associated inflammatory reactions develop in patients being treated with @DRUG$ and @DRUG$, it is still advisable to continue treatment with both drugs.	DDI-advise
DDI-DrugBank.d74.s0.p0	@DRUG$ augments the action of @DRUG$s and the muscle relaxant effects of aminoglycosides.	DDI-effect
DDI-DrugBank.d74.s0.p1	@DRUG$ augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of @DRUG$.	DDI-effect
DDI-DrugBank.d74.s0.p2	FLUOTHANE augments the action of @DRUG$s and the muscle relaxant effects of @DRUG$.	DDI-false
DDI-DrugBank.d74.s1.p0	@DRUG$ may augment the hypotension caused by the ganglionic-blocking effect of @DRUG$.	DDI-effect
DDI-DrugBank.d74.s2.p0	Caution should be exercised during the administration of @DRUG$ to patients anaesthetised with @DRUG$ as arrhythmias may be precipitated.	DDI-advise
DDI-DrugBank.d74.s3.p0	For this reason the dose of @DRUG$ should be restricted and an @DRUG$ administered as appropriate.	DDI-false
DDI-DrugBank.d74.s4.p0	Caution should also be applied for other @DRUG$, and for @DRUG$ and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d74.s4.p1	Caution should also be applied for other @DRUG$, and for aminophylline and @DRUG$ and tricyclic antidepressants, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d74.s4.p2	Caution should also be applied for other @DRUG$, and for aminophylline and theophylline and @DRUG$, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d74.s4.p3	Caution should also be applied for other sympathomimetics, and for @DRUG$ and @DRUG$ and tricyclic antidepressants, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d74.s4.p4	Caution should also be applied for other sympathomimetics, and for @DRUG$ and theophylline and @DRUG$, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d74.s4.p5	Caution should also be applied for other sympathomimetics, and for aminophylline and @DRUG$ and @DRUG$, which may also precipitate arrhythmias.	DDI-false
DDI-DrugBank.d493.s0.p0	@DRUG$: @DRUG$ has been studied in rheumatoid arthritis patients taking concomitant MTX.	DDI-false
DDI-DrugBank.d493.s0.p1	@DRUG$: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant @DRUG$.	DDI-false
DDI-DrugBank.d493.s0.p2	Methotrexate: @DRUG$ has been studied in rheumatoid arthritis patients taking concomitant @DRUG$.	DDI-false
DDI-DrugBank.d493.s1.p0	The data do not suggest the need for dose adjustment of either @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d493.s2.p0	@DRUG$: Concurrent administration of @DRUG$ (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-false
DDI-DrugBank.d493.s2.p1	@DRUG$: Concurrent administration of anakinra (an @DRUG$) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-false
DDI-DrugBank.d493.s2.p2	@DRUG$: Concurrent administration of anakinra (an interleukin-1 antagonist) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-false
DDI-DrugBank.d493.s2.p3	Anakinra: Concurrent administration of @DRUG$ (an @DRUG$) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-false
DDI-DrugBank.d493.s2.p4	Anakinra: Concurrent administration of @DRUG$ (an interleukin-1 antagonist) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-effect
DDI-DrugBank.d493.s2.p5	Anakinra: Concurrent administration of anakinra (an @DRUG$) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	DDI-effect
DDI-DrugBank.d493.s3.p0	The safety and efficacy of @DRUG$ used in combination with @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d493.s4.p0	Therefore the, combination of @DRUG$ with other @DRUG$, including HUMIRA, may also result i n similar toxicities.	DDI-effect
DDI-DrugBank.d493.s4.p1	Therefore the, combination of @DRUG$ with other TNF-blocking agents, including @DRUG$, may also result i n similar toxicities.	DDI-effect
DDI-DrugBank.d493.s4.p2	Therefore the, combination of anakinra with other @DRUG$, including @DRUG$, may also result i n similar toxicities.	DDI-false
DDI-DrugBank.d8.s0.p0	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.	DDI-effect
DDI-DrugBank.d8.s0.p1	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, opioids, or inhalation general anesthetics.	DDI-effect
DDI-DrugBank.d8.s0.p2	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, @DRUG$, opioids, or inhalation general anesthetics.	DDI-effect
DDI-DrugBank.d8.s0.p3	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, tranquilizers, @DRUG$, or inhalation general anesthetics.	DDI-effect
DDI-DrugBank.d8.s0.p4	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general @DRUG$.	DDI-effect
DDI-DrugBank.d8.s0.p5	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as @DRUG$, tranquilizers, opioids, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p6	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, @DRUG$, opioids, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p7	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, @DRUG$, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p8	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, opioids, or inhalation general @DRUG$.	DDI-false
DDI-DrugBank.d8.s0.p9	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, @DRUG$, opioids, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p10	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, @DRUG$, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p11	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, opioids, or inhalation general @DRUG$.	DDI-false
DDI-DrugBank.d8.s0.p12	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, @DRUG$, @DRUG$, or inhalation general anesthetics.	DDI-false
DDI-DrugBank.d8.s0.p13	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, @DRUG$, opioids, or inhalation general @DRUG$.	DDI-false
DDI-DrugBank.d8.s0.p14	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, @DRUG$, or inhalation general @DRUG$.	DDI-false
DDI-DrugBank.d8.s3.p0	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-mechanism
DDI-DrugBank.d8.s3.p1	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p2	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p3	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p4	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p5	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p6	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p7	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-mechanism
DDI-DrugBank.d8.s3.p8	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p9	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s4.p0	@DRUG$ reduces the clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d8.s5.p0	Therefore smaller @DRUG$ doses will be required with prolonged administration and the duration of action of @DRUG$ my be extended.	DDI-false
DDI-DrugBank.d166.s0.p0	@DRUG$ has been found to temporarily raise serum concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d166.s1.p0	@DRUG$ may potentiate the adverse effects of other @DRUG$ administered concomitantly.	DDI-effect
DDI-DrugBank.d166.s2.p0	In particular, convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs.	DDI-effect
DDI-DrugBank.d325.s0.p0	Because @DRUG$ is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of @DRUG$.	DDI-false
DDI-DrugBank.d325.s1.p0	Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of @DRUG$ should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.	DDI-advise
DDI-DrugBank.d325.s1.p1	Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of dopamine HCl should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
DDI-DrugBank.d325.s1.p2	Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of @DRUG$ should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
DDI-DrugBank.d325.s2.p0	Concurrent administration of low-dose @DRUG$ and @DRUG$ may produce an additive or potentiating effect on urine flow.	DDI-effect
DDI-DrugBank.d325.s4.p0	Cardiac effects of @DRUG$ are antagonized by @DRUG$, such as propranolol and metoprolol.	DDI-effect
DDI-DrugBank.d325.s4.p1	Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and metoprolol.	DDI-effect
DDI-DrugBank.d325.s4.p2	Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as propranolol and @DRUG$.	DDI-effect
DDI-DrugBank.d325.s4.p3	Cardiac effects of dopamine are antagonized by @DRUG$, such as @DRUG$ and metoprolol.	DDI-false
DDI-DrugBank.d325.s4.p4	Cardiac effects of dopamine are antagonized by @DRUG$, such as propranolol and @DRUG$.	DDI-false
DDI-DrugBank.d325.s4.p5	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d325.s5.p0	The peripheral vasoconstriction caused by high doses of @DRUG$ is antagonized by @DRUG$.	DDI-effect
DDI-DrugBank.d325.s6.p0	@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either @DRUG$.	DDI-false
DDI-DrugBank.d325.s6.p1	@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either alpha- or @DRUG$.	DDI-false
DDI-DrugBank.d325.s6.p2	Dopamine-induced renal and mesenteric vasodilation is not antagonized by either @DRUG-DRUG$.	DDI-false
DDI-DrugBank.d325.s7.p0	@DRUG$ (such as @DRUG$) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p1	@DRUG$ (such as haloperidol) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p2	@DRUG$ (such as haloperidol) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d325.s7.p3	Butyrophenones (such as @DRUG$) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p4	Butyrophenones (such as @DRUG$) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d325.s7.p5	Butyrophenones (such as haloperidol) and @DRUG$ can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d325.s8.p0	@DRUG$ or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.	DDI-false
DDI-DrugBank.d325.s8.p1	@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
DDI-DrugBank.d325.s8.p2	@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
DDI-DrugBank.d325.s8.p3	Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
DDI-DrugBank.d325.s8.p4	Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
DDI-DrugBank.d325.s8.p5	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as @DRUG$.	DDI-false
DDI-DrugBank.d325.s10.p0	Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon anesthetics.	DDI-advise
DDI-DrugBank.d325.s10.p1	Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving cyclopropane or @DRUG$.	DDI-advise
DDI-DrugBank.d325.s10.p2	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d325.s11.p0	It has been reported that results of studies in animals indicate that @DRUG$-induced ventricular arrhythmias during anesthesia can be reversed by @DRUG$.	DDI-effect
DDI-DrugBank.d325.s12.p0	The concomitant use of @DRUG$s, vasoconstricting agents (such as @DRUG$) and some oxytocic drugs may result in severe hypertension.	DDI-false
DDI-DrugBank.d325.s12.p1	The concomitant use of @DRUG$s, vasoconstricting agents (such as ergonovine) and some @DRUG$ may result in severe hypertension.	DDI-effect
DDI-DrugBank.d325.s12.p2	The concomitant use of vasopressors, vasoconstricting agents (such as @DRUG$) and some @DRUG$ may result in severe hypertension.	DDI-effect
DDI-DrugBank.d325.s13.p0	Administration of @DRUG$ to patients receiving @DRUG$ has been reported to lead to hypotension and bradycardia.	DDI-effect
DDI-DrugBank.d325.s14.p0	It is suggested that in patients receiving @DRUG$, alternatives to @DRUG$ should be used if anticonvulsant therapy is needed.	DDI-advise
DDI-DrugBank.d325.s14.p1	It is suggested that in patients receiving @DRUG$, alternatives to phenytoin should be used if @DRUG$ therapy is needed.	DDI-false
DDI-DrugBank.d325.s14.p2	It is suggested that in patients receiving dopamine HCl, alternatives to @DRUG$ should be used if @DRUG$ therapy is needed.	DDI-false
DDI-DrugBank.d217.s0.p0	Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	DDI-mechanism
DDI-DrugBank.d217.s1.p0	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	DDI-false
DDI-DrugBank.d217.s1.p1	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	DDI-false
DDI-DrugBank.d217.s1.p2	There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d217.s2.p0	Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted as required.	DDI-false
DDI-DrugBank.d217.s3.p0	Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with norfloxacin.	DDI-false
DDI-DrugBank.d217.s3.p1	Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	DDI-false
DDI-DrugBank.d217.s3.p2	Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with @DRUG$.	DDI-mechanism
DDI-DrugBank.d217.s4.p0	Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	DDI-false
DDI-DrugBank.d217.s5.p0	@DRUG$, including @DRUG$, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.	DDI-false
DDI-DrugBank.d217.s5.p1	@DRUG$, including norfloxacin, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
DDI-DrugBank.d217.s5.p2	@DRUG$, including norfloxacin, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
DDI-DrugBank.d217.s5.p3	Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
DDI-DrugBank.d217.s5.p4	Quinolones, including @DRUG$, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
DDI-DrugBank.d217.s5.p5	Quinolones, including norfloxacin, may enhance the effects of oral @DRUG$, including @DRUG$ or its derivatives or similar agents.	DDI-false
DDI-DrugBank.d217.s7.p0	The concomitant administration of @DRUG$ including @DRUG$ with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p1	The concomitant administration of @DRUG$ including norfloxacin with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
DDI-DrugBank.d217.s7.p2	The concomitant administration of @DRUG$ including norfloxacin with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p3	The concomitant administration of quinolones including @DRUG$ with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
DDI-DrugBank.d217.s7.p4	The concomitant administration of quinolones including @DRUG$ with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p5	The concomitant administration of quinolones including norfloxacin with @DRUG$ (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s9.p0	Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of @DRUG$ and norfloxacin.	DDI-false
DDI-DrugBank.d217.s9.p1	Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of probenecid and @DRUG$.	DDI-false
DDI-DrugBank.d217.s9.p2	Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of @DRUG$ and @DRUG$.	DDI-mechanism
DDI-DrugBank.d217.s10.p0	The concomitant use of @DRUG$ is not recommended since @DRUG$ may antagonize the antibacterial effect of Norfloxacin in the urinary tract.	DDI-false
DDI-DrugBank.d217.s10.p1	The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-false
DDI-DrugBank.d217.s10.p2	The concomitant use of nitrofurantoin is not recommended since @DRUG$ may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-effect
DDI-DrugBank.d217.s11.p0	@DRUG$, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p1	@DRUG$, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p2	@DRUG$, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p3	@DRUG$, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p4	@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s11.p5	@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s11.p6	Multivitamins, or other products containing @DRUG$ or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p7	Multivitamins, or other products containing @DRUG$ or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p8	Multivitamins, or other products containing @DRUG$ or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p9	Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s11.p10	Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s11.p11	Multivitamins, or other products containing iron or @DRUG$, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p12	Multivitamins, or other products containing iron or @DRUG$, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p13	Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s11.p14	Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s11.p15	Multivitamins, or other products containing iron or zinc, @DRUG$ or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s11.p16	Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s11.p17	Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s11.p18	Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s11.p19	Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s11.p20	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s12.p0	@DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s12.p1	@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s12.p2	@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s12.p3	Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s12.p4	Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s12.p5	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s13.p0	Some @DRUG$ have also been shown to interfere with the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d35.s0.p0	Interactions may occur between @DRUG$ supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
DDI-DrugBank.d35.s0.p1	Interactions may occur between @DRUG$ supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
DDI-DrugBank.d35.s0.p2	Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-int
DDI-DrugBank.d35.s0.p3	Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-int
DDI-DrugBank.d35.s0.p4	Interactions may occur between EPA supplements and @DRUG$ and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-false
DDI-DrugBank.d35.s0.p5	Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
DDI-DrugBank.d35.s0.p6	Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
DDI-DrugBank.d35.s0.p7	Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
DDI-DrugBank.d35.s0.p8	Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
DDI-DrugBank.d35.s0.p9	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d497.s0.p0	@DRUG$ (@DRUG$ ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.	DDI-false
DDI-DrugBank.d497.s0.p1	@DRUG$ (brinzolamide ophthalmic suspension) 1% contains a @DRUG$.	DDI-false
DDI-DrugBank.d497.s0.p2	AZOPT (@DRUG$ ophthalmic suspension) 1% contains a @DRUG$.	DDI-false
DDI-DrugBank.d497.s2.p0	However, in patients treated with oral @DRUG$, rare instances of drug interactions have occurred with high-dose @DRUG$ therapy.	DDI-int
DDI-DrugBank.d497.s3.p0	Therefore, the potential for such drug interaction should be considered in patients receiving @DRUG$ (@DRUG$ ophthalmic suspension) 1%.	DDI-false
DDI-DrugBank.d372.s0.p0	@DRUG$ accelerates the metabolism of @DRUG$;	DDI-mechanism
DDI-DrugBank.d372.s1.p0	therefore, if @DRUG$ replacement is needed, @DRUG$ should be prescribed.	DDI-false
DDI-DrugBank.d372.s2.p0	@DRUG$ diminishes the effect of @DRUG$ and warfarin.	DDI-effect
DDI-DrugBank.d372.s2.p1	@DRUG$ diminishes the effect of coumarin and @DRUG$.	DDI-effect
DDI-DrugBank.d372.s2.p2	Aminoglutethimide diminishes the effect of @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d377.s0.p0	@DRUG$ potentiates other @DRUG$ such as succinylcholine or organophosphate and carbamate insecticides.	DDI-effect
DDI-DrugBank.d377.s0.p1	@DRUG$ potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and carbamate insecticides.	DDI-effect
DDI-DrugBank.d377.s0.p2	@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG$s.	DDI-effect
DDI-DrugBank.d377.s0.p3	@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and @DRUG$s.	DDI-effect
DDI-DrugBank.d377.s0.p4	Phospholine Iodide potentiates other @DRUG$ such as @DRUG$ or organophosphate and carbamate insecticides.	DDI-false
DDI-DrugBank.d377.s0.p5	Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p6	Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or organophosphate and @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p7	Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p8	Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p9	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG-DRUG$s.	DDI-false
DDI-DrugBank.d262.s0.p0	The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	DDI-false
DDI-MedLine.d55.s0.p0	Increased hepatotoxicity of @DRUG$ by concomitant administration of @DRUG$ in the rat.	DDI-effect
DDI-MedLine.d55.s1.p0	Since @DRUG$ is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	DDI-false
DDI-MedLine.d55.s1.p1	Since @DRUG$ is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of acetaminophen. 	DDI-false
DDI-MedLine.d55.s1.p2	Since @DRUG$ is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of @DRUG$. 	DDI-false
DDI-MedLine.d55.s1.p3	Since caffeine is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of acetaminophen. 	DDI-false
DDI-MedLine.d55.s1.p4	Since caffeine is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of @DRUG$. 	DDI-false
DDI-MedLine.d55.s1.p5	Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of @DRUG$. 	DDI-false
DDI-MedLine.d55.s4.p0	Careful observations on hepatotoxicity are suggested when @DRUG$ is prescribed with @DRUG$.	DDI-effect
DDI-DrugBank.d362.s2.p0	In vitro studies demonstrated that the plasma protein binding of @DRUG$ was not affected by @DRUG$ or salicylic acid, indicating no potential for protein binding-based drug interactions.	DDI-false
DDI-DrugBank.d362.s2.p1	In vitro studies demonstrated that the plasma protein binding of @DRUG$ was not affected by warfarin or @DRUG$, indicating no potential for protein binding-based drug interactions.	DDI-false
DDI-DrugBank.d362.s2.p2	In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by @DRUG$ or @DRUG$, indicating no potential for protein binding-based drug interactions.	DDI-false
DDI-DrugBank.d362.s3.p0	In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.	DDI-false
DDI-DrugBank.d362.s3.p1	In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or erythromycin.	DDI-false
DDI-DrugBank.d362.s3.p2	In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or @DRUG$.	DDI-false
DDI-DrugBank.d362.s3.p3	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or erythromycin.	DDI-false
DDI-DrugBank.d362.s3.p4	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or @DRUG$.	DDI-false
DDI-DrugBank.d362.s3.p5	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d362.s4.p0	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-mechanism
DDI-DrugBank.d362.s4.p1	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p2	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p3	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p4	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p5	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s5.p0	Therefore, @DRUG$ should be administered with caution with intranasal @DRUG$.	DDI-advise
DDI-MedLine.d128.s1.p0	The @DRUG$ (@DRUG$)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 	DDI-false
DDI-MedLine.d128.s10.p0	On the other hand, the enhanced secretion of colonic fluid by @DRUG$, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of @DRUG$ in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 	DDI-false
DDI-MedLine.d128.s12.p0	@DRUG$ and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) 	DDI-false
DDI-MedLine.d128.s13.p0	@DRUG$ and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	DDI-false
DDI-MedLine.d128.s13.p1	@DRUG$ and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the @DRUG$ (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	DDI-effect
DDI-MedLine.d128.s13.p2	Loperamide and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) inhibited the @DRUG$ (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	DDI-effect
DDI-MedLine.d128.s15.p0	@DRUG$ (5 mg/kg, s.c.) completely antagonized the inhibitory effect of @DRUG$ and partly antagonized the effect of morphine. 	DDI-effect
DDI-MedLine.d128.s15.p1	@DRUG$ (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of @DRUG$. 	DDI-effect
DDI-MedLine.d128.s15.p2	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of @DRUG$ and partly antagonized the effect of @DRUG$. 	DDI-false
DDI-DrugBank.d40.s0.p0	No drugs are known to interfere with the conversion of @DRUG$ to @DRUG$.	DDI-false
DDI-DrugBank.d40.s1.p0	Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of @DRUG$ to @DRUG$.	DDI-false
DDI-DrugBank.d40.s4.p0	The pharmacokinetics and protein binding of @DRUG$, @DRUG$, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p1	The pharmacokinetics and protein binding of @DRUG$, phenytoin, and @DRUG$ were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p2	The pharmacokinetics and protein binding of @DRUG$, phenytoin, and diazepam were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p3	The pharmacokinetics and protein binding of @DRUG$, phenytoin, and diazepam were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p4	The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and @DRUG$ were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p5	The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and diazepam were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p6	The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and diazepam were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p7	The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and @DRUG$ were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p8	The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and @DRUG$ were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s4.p9	The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when @DRUG$ and @DRUG$ were concurrently administered in single submaximal doses.	DDI-false
DDI-DrugBank.d40.s5.p0	The most significant drug interactions following administration of @DRUG$ are expected to occur with drugs that interact with @DRUG$.	DDI-false
DDI-DrugBank.d40.s10.p0	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p1	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p2	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p3	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p4	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p5	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p6	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p7	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p8	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p9	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p10	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p11	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p12	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p13	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p14	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p15	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p16	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p17	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p18	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p19	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-mechanism
DDI-DrugBank.d40.s10.p20	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-mechanism
DDI-DrugBank.d40.s10.p21	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p22	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p23	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p24	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p25	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p26	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p27	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p28	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p29	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p30	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p31	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p32	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p33	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p34	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p35	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p36	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p37	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p38	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p39	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p40	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p41	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p42	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p43	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p44	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p45	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p46	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p47	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p48	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p49	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p50	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p51	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p52	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p53	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p54	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p55	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p56	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p57	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p58	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p59	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p60	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p61	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p62	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p63	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p64	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p65	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p66	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p67	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p68	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p69	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p70	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p71	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p72	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p73	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p74	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p75	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p76	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p77	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p78	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p79	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p80	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p81	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p82	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p83	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p84	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p85	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p86	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p87	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p88	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p89	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p90	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p91	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p92	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p93	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p94	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p95	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p96	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p97	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p98	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p99	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p100	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p101	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p102	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p103	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p104	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p105	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p106	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p107	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p108	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p109	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p110	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p111	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p112	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p113	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p114	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p115	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p116	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p117	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p118	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p119	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p120	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p121	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p122	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p123	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p124	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p125	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p126	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p127	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p128	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p129	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p130	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p131	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p132	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p133	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p134	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p135	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p136	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p137	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p138	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p139	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p140	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p141	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p142	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p143	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p144	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p145	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p146	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p147	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p148	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p149	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p150	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p151	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p152	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p153	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p154	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p155	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p156	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p157	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p158	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p159	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p160	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p161	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p162	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p163	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p164	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p165	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p166	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p167	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p168	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p169	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p170	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p171	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p172	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p173	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p174	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p175	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p176	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p177	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p178	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p179	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p180	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p181	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p182	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p183	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p184	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p185	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p186	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p187	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p188	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p189	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p190	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p191	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p192	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p193	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p194	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p195	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p196	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p197	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p198	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p199	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p200	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p201	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p202	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p203	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p204	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p205	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p206	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p207	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p208	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p209	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p210	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p211	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p212	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p213	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p214	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p215	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p216	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p217	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p218	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p219	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p220	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p221	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, @DRUG$, sulfonamides, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p222	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p223	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p224	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p225	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, @DRUG$, tolbutamide, trazodone	DDI-false
DDI-DrugBank.d40.s10.p226	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p227	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p228	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, @DRUG$, trazodone	DDI-false
DDI-DrugBank.d40.s10.p229	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, @DRUG$	DDI-false
DDI-DrugBank.d40.s10.p230	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d40.s12.p0	- Drugs that may decrease plasma @DRUG$ concentrations include: @DRUG$, chronic alcohol abuse, reserpine	DDI-mechanism
DDI-DrugBank.d40.s12.p1	- Drugs that may decrease plasma @DRUG$ concentrations include: carbamazepine, chronic @DRUG$ abuse, reserpine	DDI-mechanism
DDI-DrugBank.d40.s12.p2	- Drugs that may decrease plasma @DRUG$ concentrations include: carbamazepine, chronic alcohol abuse, @DRUG$	DDI-mechanism
DDI-DrugBank.d40.s12.p3	- Drugs that may decrease plasma phenytoin concentrations include: @DRUG$, chronic @DRUG$ abuse, reserpine	DDI-false
DDI-DrugBank.d40.s12.p4	- Drugs that may decrease plasma phenytoin concentrations include: @DRUG$, chronic alcohol abuse, @DRUG$	DDI-false
DDI-DrugBank.d40.s12.p5	- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic @DRUG$ abuse, @DRUG$	DDI-false
DDI-DrugBank.d40.s14.p0	- Drugs that may either increase or decrease plasma @DRUG$ concentrations include: @DRUG$, vaiproic acid, and sodium valproate.	DDI-mechanism
DDI-DrugBank.d40.s14.p1	- Drugs that may either increase or decrease plasma @DRUG$ concentrations include: phenobarbital, vaiproic acid, and @DRUG$.	DDI-mechanism
DDI-DrugBank.d40.s14.p2	- Drugs that may either increase or decrease plasma phenytoin concentrations include: @DRUG$, vaiproic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d40.s15.p0	Similarly, the effects of @DRUG$ on @DRUG$, valproic acid and sodium plasma valproate concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p1	Similarly, the effects of @DRUG$ on phenobarbital, @DRUG$ and sodium plasma valproate concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p2	Similarly, the effects of @DRUG$ on phenobarbital, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p3	Similarly, the effects of phenytoin on @DRUG$, @DRUG$ and sodium plasma valproate concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s15.p4	Similarly, the effects of phenytoin on @DRUG$, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s15.p5	Similarly, the effects of phenytoin on phenobarbital, @DRUG$ and sodium plasma @DRUG$ concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s17.p0	- Although not a true drug interaction, @DRUG$ may precipitate seizures in susceptible patients and @DRUG$ dosage may need to be adjusted	DDI-effect
DDI-DrugBank.d40.s19.p0	- Drugs whose efficacy is impaired by @DRUG$ include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p1	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p2	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p3	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p4	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p5	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p6	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p7	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p8	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p9	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p10	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-effect
DDI-DrugBank.d40.s19.p11	- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-effect
DDI-DrugBank.d40.s19.p12	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p13	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p14	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p15	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p16	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p17	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p18	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p19	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p20	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p21	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p22	- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p23	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p24	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p25	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p26	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p27	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p28	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p29	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p30	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p31	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p32	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p33	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p34	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p35	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p36	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p37	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p38	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p39	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p40	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p41	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p42	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p43	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p44	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p45	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p46	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p47	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p48	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p49	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p50	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p51	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p52	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p53	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p54	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p55	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p56	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p57	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p58	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p59	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p60	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p61	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p62	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p63	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p64	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p65	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p66	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p67	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p68	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, @DRUG$, quinidine, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p69	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p70	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p71	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p72	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, @DRUG$, theophylline, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p73	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p74	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p75	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, @DRUG$, vitamin D.	DDI-false
DDI-DrugBank.d40.s19.p76	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, @DRUG$.	DDI-false
DDI-DrugBank.d40.s19.p77	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, @DRUG$.	DDI-false
DDI-DrugBank.d40.s24.p0	Care should be taken when using immunoanalytical methods to measure plasma @DRUG$ concentrations following @DRUG$ administration.	DDI-false
DDI-DrugBank.d511.s0.p0	A possible drug interaction of @DRUG$ and intravenous @DRUG$ has been described.	DDI-int
DDI-DrugBank.d511.s1.p0	Concomitant treatment of four patients in the United Kingdom with @DRUG$ and intravenous @DRUG$ may have caused hypocalcemia;	DDI-effect
DDI-DrugBank.d511.s4.p0	Because of @DRUG$s tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p1	Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p2	Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p3	Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p4	Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-advise
DDI-DrugBank.d511.s4.p5	Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-advise
DDI-DrugBank.d511.s4.p6	Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	DDI-advise
DDI-DrugBank.d511.s4.p7	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p8	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s4.p9	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	DDI-false
DDI-DrugBank.d511.s6.p0	@DRUG$: The pharmacokinetics of @DRUG$ and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	DDI-false
DDI-DrugBank.d511.s6.p1	@DRUG$: The pharmacokinetics of foscarnet and @DRUG$ were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	DDI-false
DDI-DrugBank.d511.s6.p2	Ganciclovir: The pharmacokinetics of @DRUG$ and @DRUG$ were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	DDI-false
DDI-DrugBank.d479.s0.p0	The vasodilating effects of @DRUG$ may be additive with those of other @DRUG$.	DDI-effect
DDI-DrugBank.d479.s2.p0	Marked symptomatic orthostatic hypotension has been reported when @DRUG$ and @DRUG$ were used in combination.	DDI-effect
DDI-MedLine.d79.s0.p0	If taken 1 hour before @DRUG$ (@DRUG$), didanosine does not affect IDV exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s0.p1	If taken 1 hour before @DRUG$ (IDV), @DRUG$ does not affect IDV exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s0.p2	If taken 1 hour before @DRUG$ (IDV), didanosine does not affect @DRUG$ exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s0.p3	If taken 1 hour before indinavir (@DRUG$), @DRUG$ does not affect IDV exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s0.p4	If taken 1 hour before indinavir (@DRUG$), didanosine does not affect @DRUG$ exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s0.p5	If taken 1 hour before indinavir (IDV), @DRUG$ does not affect @DRUG$ exposure, despite persistent buffering effects.  	DDI-false
DDI-MedLine.d79.s1.p0	Concurrent administration of @DRUG$ and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	DDI-mechanism
DDI-MedLine.d79.s1.p1	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p2	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p3	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p4	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p5	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p6	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p7	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p8	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	DDI-false
DDI-MedLine.d79.s1.p9	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration @DRUG$ may be given safely. 	DDI-false
DDI-MedLine.d79.s2.p0	We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	DDI-false
DDI-MedLine.d79.s2.p1	We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of @DRUG$ administered 1 h after didanosine administration. 	DDI-false
DDI-MedLine.d79.s2.p2	We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after @DRUG$ administration. 	DDI-false
DDI-MedLine.d79.s2.p3	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of @DRUG$ administered 1 h after didanosine administration. 	DDI-false
DDI-MedLine.d79.s2.p4	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of indinavir administered 1 h after @DRUG$ administration. 	DDI-false
DDI-MedLine.d79.s2.p5	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of @DRUG$ administered 1 h after @DRUG$ administration. 	DDI-false
DDI-MedLine.d79.s3.p0	Median gastric pH was significantly higher when @DRUG$ was taken after @DRUG$ administration; 	DDI-mechanism
DDI-MedLine.d79.s5.p0	@DRUG$ may be taken with a light meal 1 h following the administration of 400 mg of @DRUG$.	DDI-advise
DDI-DrugBank.d168.s0.p0	This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p1	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p2	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p3	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p4	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p5	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p6	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p7	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p8	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p9	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p10	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p11	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p12	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p13	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p14	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p15	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p16	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p17	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p18	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p19	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p20	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p21	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p22	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p23	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p24	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p25	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d168.s0.p26	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d168.s0.p27	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d340.s1.p0	Coadministration of @DRUG$ and drugs primarily metabolized by CYP3A (e.g., @DRUG$) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.	DDI-false
DDI-DrugBank.d340.s3.p0	Coadministration of @DRUG$ and drugs that induce CYP3A may decrease @DRUG$ plasma concentrations and reduce its therapeutic effect.	DDI-false
DDI-DrugBank.d340.s4.p0	Coadministration of @DRUG$ and drugs that inhibit CYP3A may increase @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d340.s5.p0	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p1	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p2	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p3	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p4	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p5	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p6	Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p7	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p8	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p9	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p10	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p11	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p12	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p13	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p14	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p15	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p16	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p17	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p18	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p19	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p20	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p21	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p22	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, @DRUG$, itraconazole or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p23	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p24	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p25	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, @DRUG$ or fluconazole.	DDI-false
DDI-DrugBank.d340.s5.p26	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or @DRUG$.	DDI-false
DDI-DrugBank.d340.s5.p27	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d340.s6.p0	Drugs That Should Not Be Coadministered With @DRUG$ @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p1	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p2	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p3	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p4	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p5	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p6	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p7	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p8	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p9	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p10	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p11	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-advise
DDI-DrugBank.d340.s6.p12	Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-advise
DDI-DrugBank.d340.s6.p13	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p14	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p15	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p16	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p17	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p18	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p19	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p20	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p21	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p22	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p23	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p24	Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p25	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p26	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p27	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p28	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p29	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p30	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p31	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p32	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p33	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p34	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p35	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p36	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p37	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p38	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p39	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p40	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p41	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p42	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p43	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p44	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p45	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p46	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p47	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p48	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p49	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p50	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p51	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p52	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p53	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p54	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p55	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p56	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p57	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p58	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p59	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p60	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p61	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p62	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p63	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p64	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p65	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p66	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p67	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p68	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p69	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p70	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p71	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p72	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p73	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p74	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p75	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p76	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p77	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p78	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p79	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p80	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p81	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p82	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p83	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p84	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p85	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ @DRUG$, triazolam GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p86	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p87	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p88	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, @DRUG$ GI motility agents: cisapride	DDI-false
DDI-DrugBank.d340.s6.p89	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s6.p90	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: @DRUG$	DDI-false
DDI-DrugBank.d340.s7.p0	Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ @DRUG$: rifabutin	DDI-advise
DDI-DrugBank.d340.s7.p1	Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ Antimycobacterial agents: @DRUG$	DDI-advise
DDI-DrugBank.d340.s7.p2	Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT @DRUG$: @DRUG$	DDI-false
DDI-DrugBank.d340.s8.p0	* This table is not all inclusive ** @DRUG$ may not be effective due to decreased @DRUG$ plasma concentrations in patients taking these agents concomitantly	DDI-false
DDI-DrugBank.d340.s10.p0	@DRUG$: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
DDI-DrugBank.d340.s10.p1	@DRUG$: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
DDI-DrugBank.d340.s10.p2	@DRUG$: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
DDI-DrugBank.d340.s10.p3	Terfenadine: Administration of @DRUG$ with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
DDI-DrugBank.d340.s10.p4	Terfenadine: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
DDI-DrugBank.d340.s10.p5	Terfenadine: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
DDI-DrugBank.d340.s11.p0	therefore, @DRUG$ should not be administered concurrently with @DRUG$ because of the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-advise
DDI-DrugBank.d340.s12.p0	Because a similar interaction is likely, @DRUG$ should also not be administered concurrently with @DRUG$.	DDI-advise
DDI-DrugBank.d340.s14.p0	@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p1	@DRUG$: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p2	@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p3	@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p4	Indinavir: Coadministration of @DRUG$ with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s14.p5	Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p6	Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p7	Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p8	Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s14.p9	Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p0	@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p1	@DRUG$: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p2	@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p3	@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p4	Ritonavir: Coadministration of @DRUG$ with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s16.p5	Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p6	Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p7	Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p8	Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s16.p9	Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p0	@DRUG$: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p1	@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p2	@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p3	@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p4	@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p5	Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p6	Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s18.p7	Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p8	Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p9	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p10	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p11	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p12	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p13	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s18.p14	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p0	@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p1	@DRUG$: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p2	@DRUG$: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p3	Ketoconazole: Coadministration of @DRUG$ with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s22.p4	Ketoconazole: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p5	Ketoconazole: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s23.p0	This change was not considered clinically significant and no dose adjustment is needed when @DRUG$ and @DRUG$ are coadministered.	DDI-false
DDI-DrugBank.d340.s25.p0	@DRUG$: It is recommended that @DRUG$ be administered on an empty stomach;	DDI-false
DDI-DrugBank.d340.s26.p0	therefore, @DRUG$ should be administered (with food) one hour after or more than two hours before @DRUG$.	DDI-advise
DDI-DrugBank.d340.s27.p0	A dose adjustment is not needed when @DRUG$ is administered with @DRUG$.	DDI-advise
DDI-DrugBank.d340.s28.p0	Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with @DRUG$ or stavudine.	DDI-false
DDI-DrugBank.d340.s28.p1	Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with lamivudine or @DRUG$.	DDI-false
DDI-DrugBank.d340.s28.p2	Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d340.s30.p0	@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p1	@DRUG$: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p2	@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p3	@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p4	Rifabutin: Coadministration of @DRUG$ and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s30.p5	Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p6	Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p7	Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p8	Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s30.p9	Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s31.p0	It is recommended that the dose of @DRUG$ be reduced to one-half the usual dose when administered with @DRUG$.	DDI-advise
DDI-DrugBank.d340.s32.p0	@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s32.p1	@DRUG$: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s32.p2	@DRUG$: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s32.p3	Rifampin: Coadministration of @DRUG$ and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s32.p4	Rifampin: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s32.p5	Rifampin: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s33.p0	@DRUG$ and @DRUG$ should not be coadministered.	DDI-advise
DDI-DrugBank.d340.s35.p0	@DRUG$ and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p1	@DRUG$ and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p2	@DRUG$ and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p3	@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p4	@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p5	Ethinyl Estradiol and @DRUG$: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p6	Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p7	Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p8	Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p9	Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-mechanism
DDI-DrugBank.d340.s35.p10	Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p11	Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p12	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p13	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d340.s35.p14	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d438.s5.p0	@DRUG$ is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered @DRUG$.	DDI-false
DDI-DrugBank.d438.s7.p0	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p1	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p2	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p3	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p4	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p5	@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p6	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p7	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p8	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p9	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p10	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p11	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p12	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p13	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p14	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p15	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p16	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p17	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p18	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and @DRUG$ had no effect on gabapentin pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p19	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s7.p20	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d438.s8.p0	@DRUG$: Steady-state trough plasma @DRUG$ and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s8.p1	@DRUG$: Steady-state trough plasma carbamazepine and @DRUG$ concentrations were not affected by concomitant gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s8.p2	@DRUG$: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s8.p3	Carbamazepine: Steady-state trough plasma @DRUG$ and @DRUG$ concentrations were not affected by concomitant gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s8.p4	Carbamazepine: Steady-state trough plasma @DRUG$ and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s8.p5	Carbamazepine: Steady-state trough plasma carbamazepine and @DRUG$ concentrations were not affected by concomitant @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s10.p0	Likewise, @DRUG$ pharmacokinetics were unaltered by @DRUG$ administration.	DDI-false
DDI-DrugBank.d438.s11.p0	@DRUG$: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant gabapentin administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s11.p1	@DRUG$: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s11.p2	Valproic Acid: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s12.p0	N=17) were not different and neither were @DRUG$ pharmacokinetic parameters affected by @DRUG$.	DDI-false
DDI-DrugBank.d438.s13.p0	@DRUG$: Estimates of steady-state pharmacokinetic parameters for @DRUG$ or gabapentin (300 mg TID;	DDI-false
DDI-DrugBank.d438.s13.p1	@DRUG$: Estimates of steady-state pharmacokinetic parameters for phenobarbital or @DRUG$ (300 mg TID;	DDI-false
DDI-DrugBank.d438.s13.p2	Phenobarbital: Estimates of steady-state pharmacokinetic parameters for @DRUG$ or @DRUG$ (300 mg TID;	DDI-false
DDI-DrugBank.d438.s15.p0	@DRUG$: Coadministration (N=18) of @DRUG$ capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	DDI-false
DDI-DrugBank.d438.s15.p1	@DRUG$: Coadministration (N=18) of naproxen sodium capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	DDI-false
DDI-DrugBank.d438.s15.p2	@DRUG$: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	DDI-false
DDI-DrugBank.d438.s15.p3	Naproxen: Coadministration (N=18) of @DRUG$ capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	DDI-mechanism
DDI-DrugBank.d438.s15.p4	Naproxen: Coadministration (N=18) of @DRUG$ capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	DDI-false
DDI-DrugBank.d438.s15.p5	Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	DDI-false
DDI-DrugBank.d438.s16.p0	@DRUG$ had no effect on @DRUG$ pharmacokinetic parameters.	DDI-false
DDI-DrugBank.d438.s19.p0	@DRUG$: Coadministration of @DRUG$  (125 to 500 mg;	DDI-false
DDI-DrugBank.d438.s22.p0	Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg @DRUG$  and 21% to 22% lower, respectively, after administration of 500 mg @DRUG$ .	DDI-false
DDI-DrugBank.d438.s24.p0	@DRUG$ increases @DRUG$ AUC values by 14%.	DDI-mechanism
DDI-DrugBank.d438.s26.p0	@DRUG$: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p1	@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p2	@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p3	@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p4	@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	DDI-false
DDI-DrugBank.d438.s26.p5	Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	DDI-mechanism
DDI-DrugBank.d438.s26.p6	Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p7	Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p8	Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	DDI-false
DDI-DrugBank.d438.s26.p9	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p10	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p11	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	DDI-false
DDI-DrugBank.d438.s26.p12	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to @DRUG$ administered without morphine.	DDI-false
DDI-DrugBank.d438.s26.p13	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without @DRUG$.	DDI-false
DDI-DrugBank.d438.s26.p14	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without @DRUG$.	DDI-false
DDI-DrugBank.d438.s27.p0	@DRUG$ pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after morphine.	DDI-false
DDI-DrugBank.d438.s27.p1	@DRUG$ pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d438.s27.p2	Morphine pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d438.s29.p0	@DRUG$: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.	DDI-false
DDI-DrugBank.d438.s29.p1	@DRUG$: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	DDI-false
DDI-DrugBank.d438.s29.p2	Cimetidine: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	DDI-mechanism
DDI-DrugBank.d438.s30.p0	Thus @DRUG$ appeared to alter the renal excretion of both @DRUG$ and creatinine, an endogenous marker of renal function.	DDI-mechanism
DDI-DrugBank.d438.s31.p0	This small decrease in excretion of @DRUG$ by @DRUG$ is not expected to be of clinical importance.	DDI-mechanism
DDI-DrugBank.d438.s32.p0	The effect of @DRUG$ on @DRUG$ was not evaluated.	DDI-false
DDI-DrugBank.d438.s33.p0	Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p1	Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p2	Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p3	Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p4	Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p5	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p6	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p7	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p8	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p9	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p10	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p11	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p12	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p13	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s33.p14	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of @DRUG$ (400 mg TID;	DDI-false
DDI-DrugBank.d438.s35.p0	The Cmax of @DRUG$ was 13% higher when it was coadministered with @DRUG$;	DDI-mechanism
DDI-DrugBank.d438.s37.p0	@DRUG$ (@DRUG$ ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.	DDI-false
DDI-DrugBank.d438.s37.p1	@DRUG$ (Maalox ): @DRUG$ reduced the bioavailability of gabapentin (N=16) by about 20%.	DDI-false
DDI-DrugBank.d438.s37.p2	@DRUG$ (Maalox ): Maalox reduced the bioavailability of @DRUG$ (N=16) by about 20%.	DDI-false
DDI-DrugBank.d438.s37.p3	Antacid (@DRUG$ ): @DRUG$ reduced the bioavailability of gabapentin (N=16) by about 20%.	DDI-false
DDI-DrugBank.d438.s37.p4	Antacid (@DRUG$ ): Maalox reduced the bioavailability of @DRUG$ (N=16) by about 20%.	DDI-false
DDI-DrugBank.d438.s37.p5	Antacid (Maalox ): @DRUG$ reduced the bioavailability of @DRUG$ (N=16) by about 20%.	DDI-mechanism
DDI-DrugBank.d438.s38.p0	This decrease in bioavailability was about 5% when @DRUG$ was administered 2 hours after @DRUG$.	DDI-mechanism
DDI-DrugBank.d438.s39.p0	It is recommended that @DRUG$ be taken at least 2 hours following @DRUG$ administration.	DDI-advise
DDI-DrugBank.d438.s40.p0	Effect of @DRUG$: @DRUG$ is a blocker of renal tubular secretion.	DDI-false
DDI-DrugBank.d438.s41.p0	@DRUG$ pharmacokinetic parameters without and with @DRUG$ were comparable.	DDI-false
DDI-DrugBank.d438.s42.p0	This indicates that @DRUG$ does not undergo renal tubular secretion by the pathway that is blocked by @DRUG$.	DDI-false
DDI-DrugBank.d438.s43.p0	Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when @DRUG$ was added to other @DRUG$, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein	DDI-false
DDI-DrugBank.d314.s0.p0	@DRUG$: @DRUG$ may diminish adrenal suppression by corticosteroids.	DDI-false
DDI-DrugBank.d314.s0.p1	@DRUG$: Aminoglutethimide may diminish adrenal suppression by @DRUG$.	DDI-false
DDI-DrugBank.d314.s0.p2	Aminoglutethimide: @DRUG$ may diminish adrenal suppression by @DRUG$.	DDI-effect
DDI-DrugBank.d314.s1.p0	@DRUG$ injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p1	@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p2	@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p3	Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	DDI-advise
DDI-DrugBank.d314.s1.p4	Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-advise
DDI-DrugBank.d314.s1.p5	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s2.p0	In addition, there have been cases reported in which concomitant use of @DRUG$ and @DRUG$ was followed by cardiac enlargement and congestive heart failure.	DDI-effect
DDI-DrugBank.d314.s3.p0	@DRUG$: @DRUG$ have been reported to cause a significant decrease in corticosteroid clearance.	DDI-false
DDI-DrugBank.d314.s3.p1	@DRUG$: Macrolide antibiotics have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-false
DDI-DrugBank.d314.s3.p2	Antibiotics: @DRUG$ have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-mechanism
DDI-DrugBank.d314.s4.p0	@DRUG$: Concomitant use of @DRUG$ and corticosteroids may produce severe weakness in patients with myasthenia gravis.	DDI-false
DDI-DrugBank.d314.s4.p1	@DRUG$: Concomitant use of anticholinesterase agents and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-false
DDI-DrugBank.d314.s4.p2	Anticholinesterases: Concomitant use of @DRUG$ and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-effect
DDI-DrugBank.d314.s5.p0	If possible, @DRUG$ should be withdrawn at least 24 hours before initiating @DRUG$ therapy.	DDI-advise
DDI-DrugBank.d314.s6.p0	@DRUG$, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p1	@DRUG$, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p2	@DRUG$, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p3	Anticoagulants, oral: Co-administration of @DRUG$ and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-effect
DDI-DrugBank.d314.s6.p4	Anticoagulants, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p5	Anticoagulants, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s8.p0	@DRUG$: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.	DDI-false
DDI-DrugBank.d314.s8.p1	@DRUG$: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-false
DDI-DrugBank.d314.s8.p2	Antidiabetics: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-effect
DDI-DrugBank.d314.s10.p0	@DRUG$: @DRUG$ may increase the clearance of corticosteroids.	DDI-false
DDI-DrugBank.d314.s10.p1	@DRUG$: Cholestyramine may increase the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d314.s10.p2	Cholestyramine: @DRUG$ may increase the clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s11.p0	@DRUG$: Increased activity of both @DRUG$ and corticosteroids may occur when the two are used concurrently.	DDI-false
DDI-DrugBank.d314.s11.p1	@DRUG$: Increased activity of both cyclosporine and @DRUG$ may occur when the two are used concurrently.	DDI-false
DDI-DrugBank.d314.s11.p2	Cyclosporine: Increased activity of both @DRUG$ and @DRUG$ may occur when the two are used concurrently.	DDI-effect
DDI-DrugBank.d314.s15.p0	@DRUG$: Patients on @DRUG$ may be at increased risk of arrhythmias due to hypokalemia.	DDI-false
DDI-DrugBank.d314.s16.p0	@DRUG$: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
DDI-DrugBank.d314.s16.p1	@DRUG$: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
DDI-DrugBank.d314.s16.p2	@DRUG$: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
DDI-DrugBank.d314.s16.p3	Ephedrine: @DRUG$ may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-mechanism
DDI-DrugBank.d314.s16.p4	Ephedrine: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
DDI-DrugBank.d314.s16.p5	Ephedrine: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
DDI-DrugBank.d314.s17.p0	@DRUG$, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
DDI-DrugBank.d314.s17.p1	@DRUG$, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
DDI-DrugBank.d314.s17.p2	@DRUG$, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
DDI-DrugBank.d314.s17.p3	Estrogens, including oral @DRUG$: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
DDI-DrugBank.d314.s17.p4	Estrogens, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
DDI-DrugBank.d314.s17.p5	Estrogens, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-mechanism
DDI-DrugBank.d314.s18.p0	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p1	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p2	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p3	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
DDI-DrugBank.d314.s18.p4	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
DDI-DrugBank.d314.s18.p5	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p6	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p7	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
DDI-DrugBank.d314.s18.p8	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
DDI-DrugBank.d314.s18.p9	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
DDI-DrugBank.d314.s18.p10	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
DDI-DrugBank.d314.s18.p11	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
DDI-DrugBank.d314.s18.p12	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
DDI-DrugBank.d314.s18.p13	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
DDI-DrugBank.d314.s18.p14	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the @DRUG$ be increased.	DDI-false
DDI-DrugBank.d314.s19.p0	Drugs which inhibit CYP 3A4 (e.g., @DRUG$, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
DDI-DrugBank.d314.s19.p1	Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
DDI-DrugBank.d314.s19.p2	Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s19.p3	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
DDI-DrugBank.d314.s19.p4	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s19.p5	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s21.p0	Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., @DRUG$, @DRUG$) may increase their clearance, resulting in decreased plasma concentration.	DDI-false
DDI-DrugBank.d314.s22.p0	@DRUG$: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-false
DDI-DrugBank.d314.s22.p1	@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-false
DDI-DrugBank.d314.s22.p2	@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s22.p3	Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-mechanism
DDI-DrugBank.d314.s22.p4	Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s22.p5	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s23.p0	In addition, @DRUG$ alone can inhibit adrenal @DRUG$ synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.	DDI-effect
DDI-DrugBank.d314.s24.p0	@DRUG$ (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p1	@DRUG$ (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p2	@DRUG$ (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p3	@DRUG$ (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p4	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p5	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p6	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p7	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p8	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-effect
DDI-DrugBank.d314.s24.p9	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-effect
DDI-DrugBank.d314.s25.p0	@DRUG$ should be used cautiously in conjunction with @DRUG$ in hypoprothrombinemia.	DDI-advise
DDI-DrugBank.d314.s26.p0	The clearance of @DRUG$ may be increased with concurrent use of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s27.p0	@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with dexamethasone co-administration, leading to alterations in seizure control.	DDI-false
DDI-DrugBank.d314.s27.p1	@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-false
DDI-DrugBank.d314.s27.p2	Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-mechanism
DDI-DrugBank.d314.s29.p0	@DRUG$: Co-administration with @DRUG$ should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.	DDI-false
DDI-DrugBank.d314.s30.p0	@DRUG$: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.	DDI-false
DDI-DrugBank.d314.s30.p1	@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-false
DDI-DrugBank.d314.s30.p2	@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-false
DDI-DrugBank.d314.s30.p3	Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-effect
DDI-DrugBank.d314.s30.p4	Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-effect
DDI-DrugBank.d314.s30.p5	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG-DRUG$ due to inhibition of antibody response.	DDI-false
DDI-DrugBank.d314.s31.p0	@DRUG$ may also potentiate the replication of some organisms contained in @DRUG$.	DDI-effect
DDI-DrugBank.d314.s32.p0	Routine administration of @DRUG$ or toxoids should be deferred until @DRUG$ therapy is discontinued if possible.	DDI-advise
DDI-DrugBank.d502.s0.p0	@DRUG$ should be used with caution in patients who are receiving a @DRUG$ orally because of the potential for additive effects on systemic beta-blockade.	DDI-advise
DDI-DrugBank.d502.s1.p0	Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.	DDI-advise
DDI-DrugBank.d22.s0.p0	@DRUG$ may decrease the amount of @DRUG$ (Lanoxin, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
DDI-DrugBank.d22.s0.p1	@DRUG$ may decrease the amount of digoxin (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
DDI-DrugBank.d22.s0.p2	@DRUG$ may decrease the amount of digoxin (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
DDI-DrugBank.d22.s0.p3	Aminosalicylic acid may decrease the amount of @DRUG$ (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-false
DDI-DrugBank.d22.s0.p4	Aminosalicylic acid may decrease the amount of @DRUG$ (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
DDI-DrugBank.d22.s0.p5	Aminosalicylic acid may decrease the amount of digoxin (@DRUG$, @DRUG$) that gets absorbed into your body.	DDI-false
DDI-DrugBank.d22.s1.p0	In the case that you are taking @DRUG$ while taking @DRUG$, higher doses of digoxin may be needed.	DDI-advise
DDI-DrugBank.d22.s1.p1	In the case that you are taking @DRUG$ while taking aminosalicylic acid, higher doses of @DRUG$ may be needed.	DDI-false
DDI-DrugBank.d22.s1.p2	In the case that you are taking digoxin while taking @DRUG$, higher doses of @DRUG$ may be needed.	DDI-false
DDI-DrugBank.d22.s2.p0	@DRUG$ may also decrease the absorption of @DRUG$, which can lead to a deficiency.	DDI-mechanism
DDI-DrugBank.d22.s3.p0	Therefore you may need to take a @DRUG$ supplement while taking @DRUG$.	DDI-advise
DDI-DrugBank.d116.s0.p0	Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
DDI-DrugBank.d161.s1.p0	For information on the pharmacokinetics of @DRUG$ and @DRUG$ in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.	DDI-false
DDI-DrugBank.d270.s9.p0	The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex.	DDI-false
DDI-DrugBank.d270.s9.p1	The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex.	DDI-int
DDI-DrugBank.d270.s9.p2	The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex.	DDI-false
DDI-DrugBank.d270.s11.p0	When @DRUG$ is co-administered with @DRUG$, anticoagulation levels should be monitored frequently.	DDI-advise
DDI-DrugBank.d270.s18.p0	@DRUG$ exposure was significantly decreased by @DRUG$;	DDI-mechanism
DDI-DrugBank.d270.s20.p0	Alternatives to @DRUG$,such as @DRUG$, should be considered.	DDI-false
DDI-DrugBank.d270.s24.p0	@DRUG$ and @DRUG$	DDI-false
DDI-DrugBank.d270.s25.p0	@DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d270.s26.p0	Oral @DRUG$ and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking @DRUG$, since nevirapinemay lower the plasma levels of thesemedications.	DDI-advise
DDI-DrugBank.d270.s36.p0	@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.	DDI-advise
DDI-DrugBank.d270.s36.p1	@DRUG$ and ketoconazole should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	DDI-false
DDI-DrugBank.d270.s36.p2	Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	DDI-false
DDI-DrugBank.d270.s37.p0	@DRUG$/@DRUG$	DDI-false
DDI-DrugBank.d270.s39.p0	A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine.	DDI-false
DDI-DrugBank.d270.s39.p1	A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
DDI-DrugBank.d270.s39.p2	A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
DDI-DrugBank.d270.s42.p0	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p1	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p2	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p3	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p4	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p5	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p6	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p7	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-advise
DDI-DrugBank.d270.s42.p8	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p9	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s45.p0	The appropriate dose for @DRUG$ incombination with @DRUG$, with respectto safety and efficacy, has not been established.	DDI-false
DDI-DrugBank.d270.s53.p0	@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-advise
DDI-DrugBank.d270.s53.p1	@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
DDI-DrugBank.d270.s53.p2	Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
DDI-DrugBank.d270.s54.p0	Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead.	DDI-false
DDI-DrugBank.d270.s58.p0	aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and @DRUG$ concurrently, and evidence of decreased plasma concentrations of methadone.	DDI-effect
DDI-DrugBank.d270.s58.p1	aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and methadone concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d270.s58.p2	aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d270.s63.p0	@DRUG$, @DRUG$, lidocaine	DDI-false
DDI-DrugBank.d270.s63.p1	@DRUG$, disopyramide, @DRUG$	DDI-false
DDI-DrugBank.d270.s63.p2	Amiodarone, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d270.s65.p0	@DRUG$, @DRUG$, ethosuximide	DDI-false
DDI-DrugBank.d270.s65.p1	@DRUG$, clonazepam, @DRUG$	DDI-false
DDI-DrugBank.d270.s65.p2	Carbamazepine, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d270.s69.p0	@DRUG$, @DRUG$, verapamil	DDI-false
DDI-DrugBank.d270.s69.p1	@DRUG$, nifedipine, @DRUG$	DDI-false
DDI-DrugBank.d270.s69.p2	Diltiazem, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d270.s75.p0	@DRUG$, @DRUG$, sirolimus	DDI-false
DDI-DrugBank.d270.s75.p1	@DRUG$, tacrolimus, @DRUG$	DDI-false
DDI-DrugBank.d270.s75.p2	Cyclosporin, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d552.s0.p0	@DRUG$ should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-advise
DDI-DrugBank.d552.s0.p1	@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-advise
DDI-DrugBank.d552.s0.p2	@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-advise
DDI-DrugBank.d552.s0.p3	@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-advise
DDI-DrugBank.d552.s0.p4	@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-advise
DDI-DrugBank.d552.s0.p5	Nabilone should be administered with caution to patients who are taking other @DRUG$ or @DRUG$, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p6	Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p7	Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p8	Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p9	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p10	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p11	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p12	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p13	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s0.p14	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, @DRUG$ and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	DDI-false
DDI-DrugBank.d552.s1.p0	@DRUG$ has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, alcohol or codeine.	DDI-effect
DDI-DrugBank.d552.s1.p1	@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, alcohol or codeine.	DDI-effect
DDI-DrugBank.d552.s1.p2	@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, @DRUG$ or codeine.	DDI-effect
DDI-DrugBank.d552.s1.p3	@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or @DRUG$.	DDI-effect
DDI-DrugBank.d552.s1.p4	Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, @DRUG$, alcohol or codeine.	DDI-false
DDI-DrugBank.d552.s1.p5	Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, @DRUG$ or codeine.	DDI-false
DDI-DrugBank.d552.s1.p6	Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, alcohol or @DRUG$.	DDI-false
DDI-DrugBank.d552.s1.p7	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, @DRUG$ or codeine.	DDI-false
DDI-DrugBank.d552.s1.p8	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, alcohol or @DRUG$.	DDI-false
DDI-DrugBank.d552.s1.p9	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d67.s0.p0	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, @DRUG$ 7.5 mg (1.5 times the daily dose) once daily was coadministered with @DRUG$ 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.	DDI-false
DDI-DrugBank.d67.s0.p1	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, @DRUG$ 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or @DRUG$ 200 mg every 12 hours for 10 days.	DDI-false
DDI-DrugBank.d67.s0.p2	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with @DRUG$ 500 mg every 8 hours or @DRUG$ 200 mg every 12 hours for 10 days.	DDI-false
DDI-DrugBank.d67.s1.p0	In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p1	In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p2	In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p3	In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p4	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p5	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p6	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p7	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p8	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s1.p9	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	DDI-false
DDI-DrugBank.d67.s2.p0	Although increased plasma concentrations (C max and AUC 0-24 hrs) of @DRUG$ and @DRUG$ were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	DDI-false
DDI-DrugBank.d67.s2.p1	Although increased plasma concentrations (C max and AUC 0-24 hrs) of @DRUG$ and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	DDI-false
DDI-DrugBank.d67.s2.p2	Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and @DRUG$ were observed , there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	DDI-false
DDI-DrugBank.d67.s3.p0	Table 1 Changes in @DRUG$ and @DRUG$ Pharmacokinetics in Healthy Male and Female Volunteers	DDI-false
DDI-DrugBank.d67.s5.p0	@DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d507.s0.p0	The potential for increased sedation when @DRUG$ is given with other @DRUG$ should be appreciated.	DDI-effect
DDI-DrugBank.d507.s1.p0	The administration of @DRUG$ concomitantly with known microsomal enzyme inducer (@DRUG$ or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	DDI-mechanism
DDI-DrugBank.d507.s1.p1	The administration of @DRUG$ concomitantly with known microsomal enzyme inducer (phenobarbital or @DRUG$) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	DDI-mechanism
DDI-DrugBank.d507.s1.p2	The administration of guanfacine concomitantly with known microsomal enzyme inducer (@DRUG$ or @DRUG$) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	DDI-false
DDI-DrugBank.d507.s4.p0	@DRUG$ decrease the hypotensive effect of @DRUG$.	DDI-effect
DDI-DrugBank.d507.s5.p0	@DRUG$ (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p1	@DRUG$ (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p2	@DRUG$ (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s5.p3	Noncardioselective beta-blockers (@DRUG$,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p4	Noncardioselective beta-blockers (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s5.p5	Noncardioselective beta-blockers (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s7.p0	The gradual withdrawal of @DRUG$ or a @DRUG$ could be substituted.	DDI-false
DDI-DrugBank.d507.s8.p0	@DRUG$: Ten patients who were stabilized on oral @DRUG$ were given guanfacine, 1-2 mg/day, for 4 weeks.	DDI-false
DDI-DrugBank.d507.s8.p1	@DRUG$: Ten patients who were stabilized on oral anticoagulants were given @DRUG$, 1-2 mg/day, for 4 weeks.	DDI-false
DDI-DrugBank.d507.s8.p2	Anticoagulants: Ten patients who were stabilized on oral @DRUG$ were given @DRUG$, 1-2 mg/day, for 4 weeks.	DDI-false
DDI-DrugBank.d507.s10.p0	In several well-controlled studies, @DRUG$ was administered together with @DRUG$ with no drug interactions reported.	DDI-false
DDI-DrugBank.d507.s12.p0	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p1	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p2	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p3	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p4	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p5	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p6	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p7	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p8	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p9	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p10	The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p11	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p12	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p13	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p14	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p15	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p16	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p17	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p18	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p19	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p20	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p21	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p22	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p23	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p24	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p25	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p26	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p27	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p28	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p29	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p30	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p31	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p32	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p33	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p34	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p35	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p36	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p37	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p38	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p39	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p40	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p41	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p42	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p43	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p44	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p45	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p46	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p47	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p48	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p49	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p50	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p51	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p52	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p53	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p54	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p55	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p56	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p57	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p58	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p59	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p60	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), @DRUG$ (13), insulin (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p61	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p62	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p63	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), @DRUG$ (10), and beta blockers (10).	DDI-false
DDI-DrugBank.d507.s12.p64	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d507.s12.p65	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and @DRUG$ (10).	DDI-false
DDI-DrugBank.d326.s0.p0	@DRUG$ - Taking @DRUG$ and a phenothiazine together may increase the risk of convulsions (seizures).	DDI-false
DDI-DrugBank.d326.s0.p1	@DRUG$ - Taking piperazine and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-false
DDI-DrugBank.d326.s0.p2	Phenothiazines - Taking @DRUG$ and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-effect
DDI-DrugBank.d326.s1.p0	@DRUG$ (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of piperazine.	DDI-false
DDI-DrugBank.d326.s1.p1	@DRUG$ (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
DDI-DrugBank.d326.s1.p2	@DRUG$ (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
DDI-DrugBank.d326.s1.p3	@DRUG$ (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
DDI-DrugBank.d326.s1.p4	Pyrantel (e.g., @DRUG$) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
DDI-DrugBank.d326.s1.p5	Pyrantel (e.g., @DRUG$) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
DDI-DrugBank.d326.s1.p6	Pyrantel (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
DDI-DrugBank.d326.s1.p7	Pyrantel (e.g., Antiminth) - Taking @DRUG$ and @DRUG$ together may decrease the effects of piperazine.	DDI-effect
DDI-DrugBank.d326.s1.p8	Pyrantel (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of @DRUG$.	DDI-false
DDI-DrugBank.d326.s1.p9	Pyrantel (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of @DRUG$.	DDI-false
DDI-MedLine.d104.s0.p0	The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s0.p1	The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s0.p2	The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s0.p3	The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s0.p4	The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s0.p5	The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.  	DDI-false
DDI-MedLine.d104.s2.p0	injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior. 	DDI-false
DDI-MedLine.d104.s3.p0	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found. 	DDI-false
DDI-MedLine.d104.s3.p1	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found. 	DDI-false
DDI-MedLine.d104.s3.p2	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found. 	DDI-false
DDI-MedLine.d104.s4.p0	The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion. 	DDI-effect
DDI-MedLine.d104.s8.p0	In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and L-CCG-1 was carried out.	DDI-false
DDI-MedLine.d104.s8.p1	In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and L-CCG-1 was carried out.	DDI-false
DDI-MedLine.d104.s8.p2	In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and @DRUG$ was carried out.	DDI-false
DDI-MedLine.d104.s8.p3	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, @DRUG$, and L-CCG-1 was carried out.	DDI-false
DDI-MedLine.d104.s8.p4	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and @DRUG$ was carried out.	DDI-false
DDI-MedLine.d104.s8.p5	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and @DRUG$ was carried out.	DDI-false
DDI-DrugBank.d439.s0.p0	@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	DDI-effect
DDI-MedLine.d116.s0.p0	@DRUG$ and @DRUG$: a drug interaction.  	DDI-int
DDI-MedLine.d116.s1.p0	The drug interaction between @DRUG$ and @DRUG$ is not well known. 	DDI-int
DDI-MedLine.d116.s2.p0	@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously. 	DDI-mechanism
DDI-MedLine.d116.s3.p0	The concomitant administration of @DRUG$ and @DRUG$ resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	DDI-mechanism
DDI-MedLine.d116.s3.p1	The concomitant administration of @DRUG$ and warfarin resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect. 	DDI-false
DDI-MedLine.d116.s3.p2	The concomitant administration of rifampin and @DRUG$ resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect. 	DDI-false
DDI-MedLine.d116.s4.p0	Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%. 	DDI-mechanism
DDI-MedLine.d116.s5.p0	This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$. 	DDI-mechanism
DDI-MedLine.d116.s6.p0	The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	DDI-effect
DDI-MedLine.d116.s6.p1	The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal. 	DDI-false
DDI-MedLine.d116.s6.p2	The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal. 	DDI-false
DDI-MedLine.d116.s6.p3	The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal. 	DDI-false
DDI-MedLine.d116.s6.p4	The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal. 	DDI-false
DDI-MedLine.d116.s6.p5	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal. 	DDI-false
DDI-MedLine.d21.s2.p0	Treatment with @DRUG$ can directly interfere with blood glucose levels or may interact with @DRUG$. 	DDI-int
DDI-MedLine.d21.s6.p0	@DRUG$ (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p1	@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p2	@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p3	@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p4	Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p5	Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p6	Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p7	Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p8	Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s6.p9	Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	DDI-false
DDI-MedLine.d21.s8.p0	An oral @DRUG$ overload of 1 ml of a 50% @DRUG$ solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 	DDI-false
DDI-MedLine.d21.s9.p0	@DRUG$ and @DRUG$ did not change fasting or overload glycemia. 	DDI-false
DDI-MedLine.d21.s10.p0	@DRUG$ and @DRUG$ increased blood glucose at different times after the glucose overload. 	DDI-false
DDI-MedLine.d21.s10.p1	@DRUG$ and moclobemide increased blood @DRUG$ at different times after the glucose overload. 	DDI-false
DDI-MedLine.d21.s10.p2	Fluoxetine and @DRUG$ increased blood @DRUG$ at different times after the glucose overload. 	DDI-false
DDI-MedLine.d21.s11.p0	@DRUG$ neutralized the increase of glycemia induced by oral @DRUG$ overload. 	DDI-false
DDI-MedLine.d21.s12.p0	In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of @DRUG$ tolerance 30 min after @DRUG$ overload. 	DDI-false
DDI-MedLine.d21.s13.p0	Again, @DRUG$ neutralized the increase in glycemia after @DRUG$ overload both in diabetic and non-diabetic rats. 	DDI-false
DDI-DrugBank.d248.s0.p0	May interact @DRUG$ (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p1	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p2	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p3	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p4	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
DDI-DrugBank.d248.s0.p5	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p6	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p7	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p8	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
DDI-DrugBank.d248.s0.p9	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p10	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p11	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
DDI-DrugBank.d248.s0.p12	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), @DRUG$ (increased effect of corticosteroids).	DDI-false
DDI-DrugBank.d248.s0.p13	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of @DRUG$).	DDI-false
DDI-DrugBank.d248.s0.p14	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of @DRUG$).	DDI-false
DDI-DrugBank.d252.s0.p0	Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and epinephrine may occur.	DDI-false
DDI-DrugBank.d252.s0.p1	Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur.	DDI-false
DDI-DrugBank.d252.s0.p2	Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and @DRUG$ may occur.	DDI-effect
DDI-DrugBank.d252.s1.p0	Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.	DDI-advise
DDI-DrugBank.d252.s2.p0	Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.	DDI-advise
DDI-DrugBank.d252.s4.p0	The concomitant use of @DRUG$ with @DRUG$ and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.	DDI-effect
DDI-DrugBank.d252.s4.p1	The concomitant use of @DRUG$ with digitalis and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	DDI-effect
DDI-DrugBank.d252.s4.p2	The concomitant use of beta-adrenergic blocking agents with @DRUG$ and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	DDI-false
DDI-DrugBank.d252.s5.p0	@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism.	DDI-mechanism
DDI-DrugBank.d422.s0.p0	Catecholamine-depleting drugs, e.g., @DRUG$, may have an additive effect when given with @DRUG$.	DDI-effect
DDI-DrugBank.d422.s1.p0	Patients treated concurrently with @DRUG$ (@DRUG$) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.	DDI-false
DDI-DrugBank.d422.s2.p0	A study of interaction between @DRUG$ and @DRUG$ showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p1	A study of interaction between @DRUG$ and warfarin showed that concomitant administration of @DRUG$ and warfarin does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p2	A study of interaction between @DRUG$ and warfarin showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p3	A study of interaction between @DRUG$ and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p4	A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of @DRUG$ and warfarin does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p5	A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p6	A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of BREVIBLOC and warfarin does not alter @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p7	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of @DRUG$ and @DRUG$ does not alter warfarin plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p8	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of @DRUG$ and warfarin does not alter @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d422.s2.p9	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d422.s3.p0	@DRUG$ concentrations were equivocally higher when given with @DRUG$, but this is not likely to be clinically important.	DDI-mechanism
DDI-DrugBank.d422.s4.p0	When @DRUG$ and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.	DDI-mechanism
DDI-DrugBank.d422.s4.p1	When @DRUG$ and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	DDI-false
DDI-DrugBank.d422.s4.p2	When digoxin and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	DDI-false
DDI-DrugBank.d422.s5.p0	@DRUG$ did not affect @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d422.s6.p0	When intravenous @DRUG$ and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p1	When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p2	When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p3	When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	DDI-false
DDI-DrugBank.d422.s6.p4	When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p5	When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p6	When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	DDI-false
DDI-DrugBank.d422.s6.p7	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	DDI-false
DDI-DrugBank.d422.s6.p8	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	DDI-false
DDI-DrugBank.d422.s6.p9	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of @DRUG$.	DDI-mechanism
DDI-DrugBank.d422.s8.p0	The effect of @DRUG$ on the duration of @DRUG$-induced neuromuscular blockade was studied in patients undergoing surgery.	DDI-false
DDI-DrugBank.d422.s9.p0	The onset of neuromuscular blockade by @DRUG$ was unaffected by @DRUG$, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.	DDI-effect
DDI-DrugBank.d422.s10.p0	Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, succinylcholine or warfarin.	DDI-advise
DDI-DrugBank.d422.s10.p1	Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, succinylcholine or warfarin.	DDI-advise
DDI-DrugBank.d422.s10.p2	Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, morphine, @DRUG$ or warfarin.	DDI-advise
DDI-DrugBank.d422.s10.p3	Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or @DRUG$.	DDI-advise
DDI-DrugBank.d422.s10.p4	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, @DRUG$, succinylcholine or warfarin.	DDI-false
DDI-DrugBank.d422.s10.p5	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d422.s10.p6	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, succinylcholine or @DRUG$.	DDI-false
DDI-DrugBank.d422.s10.p7	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d422.s10.p8	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, succinylcholine or @DRUG$.	DDI-false
DDI-DrugBank.d422.s10.p9	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d422.s13.p0	Caution should be exercised when considering the use of @DRUG$ and @DRUG$ in patients with depressed myocardial function.	DDI-advise
DDI-DrugBank.d422.s15.p0	Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-advise
DDI-DrugBank.d422.s15.p1	Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, @DRUG$, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-advise
DDI-DrugBank.d422.s15.p2	Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-advise
DDI-DrugBank.d422.s15.p3	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, @DRUG$, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-false
DDI-DrugBank.d422.s15.p4	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, epinephrine, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-false
DDI-DrugBank.d422.s15.p5	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, @DRUG$, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	DDI-false
DDI-DrugBank.d42.s0.p0	The potential for clinically significant drug-drug interactions posed by @DRUG$ and @DRUG$ appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.	DDI-false
DDI-DrugBank.d42.s0.p1	The potential for clinically significant drug-drug interactions posed by @DRUG$ and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because @DRUG$ is eliminated by multiple routes.	DDI-false
DDI-DrugBank.d42.s0.p2	The potential for clinically significant drug-drug interactions posed by dolasetron and @DRUG$ appears to be low for drugs commonly used in chemotherapy or surgery, because @DRUG$ is eliminated by multiple routes.	DDI-false
DDI-DrugBank.d42.s1.p0	Blood levels of @DRUG$ increased 24% when @DRUG$ was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	DDI-false
DDI-DrugBank.d42.s1.p1	Blood levels of @DRUG$ increased 24% when dolasetron was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	DDI-false
DDI-DrugBank.d42.s1.p2	Blood levels of @DRUG$ increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	DDI-false
DDI-DrugBank.d42.s1.p3	Blood levels of hydrodolasetron increased 24% when @DRUG$ was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	DDI-mechanism
DDI-DrugBank.d42.s1.p4	Blood levels of hydrodolasetron increased 24% when @DRUG$ was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	DDI-mechanism
DDI-DrugBank.d42.s1.p5	Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	DDI-false
DDI-DrugBank.d42.s4.p0	In patients taking @DRUG$, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p1	In patients taking @DRUG$, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p2	In patients taking @DRUG$, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p3	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p4	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p5	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p6	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p7	In patients taking furosemide, @DRUG$, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p8	In patients taking furosemide, @DRUG$, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p9	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p10	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p11	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p12	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p13	In patients taking furosemide, nifedipine, @DRUG$, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p14	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p15	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p16	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p17	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p18	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p19	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p20	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p21	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p22	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p23	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p24	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p25	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p26	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p27	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s5.p0	Clearance of @DRUG$ decreased by about 27% when @DRUG$ was administered intravenously concomitantly with atenolol.	DDI-false
DDI-DrugBank.d42.s5.p1	Clearance of @DRUG$ decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with @DRUG$.	DDI-false
DDI-DrugBank.d42.s5.p2	Clearance of hydrodolasetron decreased by about 27% when @DRUG$ was administered intravenously concomitantly with @DRUG$.	DDI-mechanism
DDI-DrugBank.d42.s7.p0	@DRUG$ did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p1	@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p2	@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p3	@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p4	@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p5	Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (@DRUG$, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p6	Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p7	Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p8	Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p9	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p10	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p11	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p12	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, @DRUG$, cyclophosphamide) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p13	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, doxorubicin, @DRUG$) in four murine models.	DDI-false
DDI-DrugBank.d42.s7.p14	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, @DRUG$, @DRUG$) in four murine models.	DDI-false
DDI-DrugBank.d378.s0.p0	Renal function should be monitored carefully if high doses of @DRUG$ are to be administered with @DRUG$ because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.	DDI-advise
DDI-DrugBank.d378.s0.p1	Renal function should be monitored carefully if high doses of @DRUG$ are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of @DRUG$.	DDI-false
DDI-DrugBank.d378.s0.p2	Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with @DRUG$ because of the increased potential of nephrotoxicity and ototoxicity of @DRUG$.	DDI-false
DDI-DrugBank.d378.s1.p0	Nephrotoxicity has been reported following concomitant administration of other @DRUG$ with potent @DRUG$ such as furosemide.	DDI-effect
DDI-DrugBank.d378.s1.p1	Nephrotoxicity has been reported following concomitant administration of other @DRUG$ with potent diuretics such as @DRUG$.	DDI-effect
DDI-DrugBank.d378.s1.p2	Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent @DRUG$ such as @DRUG$.	DDI-false
DDI-DrugBank.d548.s0.p0	Potential for Other Drugs to Affect @DRUG$: Both CYP1A2 and CYP2D6 are responsible for @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d548.s1.p0	Inhibitors of CYP1A2: Concomitant use of @DRUG$ with @DRUG$, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.	DDI-mechanism
DDI-DrugBank.d548.s1.p1	Inhibitors of CYP1A2: Concomitant use of @DRUG$ with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of @DRUG$.	DDI-false
DDI-DrugBank.d548.s1.p2	Inhibitors of CYP1A2: Concomitant use of duloxetine with @DRUG$, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of @DRUG$.	DDI-false
DDI-DrugBank.d548.s3.p0	Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.	DDI-false
DDI-DrugBank.d548.s3.p1	Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d548.s3.p2	Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d548.s4.p0	@DRUG$ (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.	DDI-mechanism
DDI-DrugBank.d548.s4.p1	@DRUG$ (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	DDI-false
DDI-DrugBank.d548.s4.p2	Paroxetine (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	DDI-false
DDI-DrugBank.d548.s5.p0	Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d548.s6.p0	Potential for @DRUG$ to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that @DRUG$ does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.	DDI-false
DDI-DrugBank.d548.s8.p0	When @DRUG$ was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of @DRUG$, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.	DDI-mechanism
DDI-DrugBank.d548.s8.p1	When @DRUG$ was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of @DRUG$ increased 3-fold.	DDI-false
DDI-DrugBank.d548.s8.p2	When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of @DRUG$, a CYP2D6 substrate, the AUC of @DRUG$ increased 3-fold.	DDI-false
DDI-DrugBank.d548.s9.p0	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p1	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p2	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p3	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p4	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p5	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p6	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p7	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p8	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p9	Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-advise
DDI-DrugBank.d548.s9.p10	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p11	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p12	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p13	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p14	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p15	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p16	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p17	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p18	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p19	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p20	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p21	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p22	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p23	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p24	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p25	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p26	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p27	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p28	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p29	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p30	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p31	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p32	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p33	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p34	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p35	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p36	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p37	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p38	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p39	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p40	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p41	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p42	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p43	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p44	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p45	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p46	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p47	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p48	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p49	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p50	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p51	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p52	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., @DRUG$, flecainide), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p53	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s9.p54	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d548.s10.p0	Plasma @DRUG$ concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p1	Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p2	Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with @DRUG$.	DDI-false
DDI-DrugBank.d548.s10.p3	Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p4	Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with @DRUG$.	DDI-false
DDI-DrugBank.d548.s10.p5	Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d548.s11.p0	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, @DRUG$ and thioridazine should not be co-administered.	DDI-false
DDI-DrugBank.d548.s11.p1	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, Duloxetine and @DRUG$ should not be co-administered.	DDI-false
DDI-DrugBank.d548.s11.p2	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, @DRUG$ and @DRUG$ should not be co-administered.	DDI-advise
DDI-DrugBank.d548.s13.p0	@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p1	@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p2	@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p3	@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p4	@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	DDI-false
DDI-DrugBank.d548.s13.p5	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p6	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p7	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p8	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	DDI-false
DDI-DrugBank.d548.s13.p9	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p10	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p11	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	DDI-false
DDI-DrugBank.d548.s13.p12	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	DDI-false
DDI-DrugBank.d548.s13.p13	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	DDI-false
DDI-DrugBank.d548.s13.p14	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by @DRUG$.	DDI-false
DDI-DrugBank.d548.s14.p0	In the @DRUG$ clinical trials database, three @DRUG$-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.	DDI-false
DDI-DrugBank.d548.s21.p0	However, co-administration of @DRUG$ with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p1	However, co-administration of @DRUG$ with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p2	However, co-administration of @DRUG$ with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p3	However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p4	However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p5	However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p6	However, co-administration of Duloxetine with @DRUG$- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p7	However, co-administration of Duloxetine with @DRUG$- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p8	However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p9	However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p10	However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p11	However, co-administration of Duloxetine with aluminum- and @DRUG$-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p12	However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p13	However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p14	However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p15	However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p16	However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p17	However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p18	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p19	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s21.p20	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	DDI-false
DDI-DrugBank.d548.s22.p0	It is unknown whether the concomitant administration of @DRUG$ affects @DRUG$ absorption.	DDI-false
DDI-DrugBank.d7.s0.p0	The rate of metabolism and the leukopenic activity of @DRUG$ reportedly are increased by chronic administration of high doses of @DRUG$.	DDI-mechanism
DDI-DrugBank.d7.s1.p0	The physician should be alert for possible combined drug actions, desirable or undesirable, involving @DRUG$ even though @DRUG$ has been used successfully concurrently with other drugs, including other cytotoxic drugs.	DDI-false
DDI-DrugBank.d7.s2.p0	@DRUG$ treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of @DRUG$.	DDI-effect
DDI-DrugBank.d52.s0.p0	Concomitant treatment with @DRUG$ (eg, rt-PA or @DRUG$) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation	DDI-false
DDI-DrugBank.d52.s0.p1	Concomitant treatment with @DRUG$ (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of @DRUG$ on aPTT prolongation	DDI-false
DDI-DrugBank.d52.s0.p2	Concomitant treatment with thrombolytics (eg, rt-PA or @DRUG$) may: - increase the risk of bleeding complications - considerably enhance the effect of @DRUG$ on aPTT prolongation	DDI-false
DDI-DrugBank.d52.s1.p0	Concomitant treatment with @DRUG$ (@DRUG$) and drugs that affect platelet function may also increase the risk of bleeding.	DDI-false
DDI-DrugBank.d341.s1.p0	However, it was observed that the pharmacokinetics of @DRUG$  was unaltered by concomitant @DRUG$ in rheumatoid arthritis patients.	DDI-false
DDI-DrugBank.d341.s2.p0	In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).	DDI-effect
DDI-DrugBank.d341.s2.p1	In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
DDI-DrugBank.d341.s2.p2	In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
DDI-DrugBank.d341.s3.p0	Two percent of patients treated concurrently with @DRUG$  and @DRUG$ developed neutropenia (ANC   1 x 109/L).	DDI-effect
DDI-DrugBank.d341.s4.p0	Patients in a clinical study who were on established therapy with @DRUG$, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.	DDI-effect
DDI-DrugBank.d341.s4.p1	Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
DDI-DrugBank.d341.s4.p2	Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
DDI-DrugBank.d341.s4.p3	Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
DDI-DrugBank.d341.s4.p4	Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
DDI-DrugBank.d341.s4.p5	Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or @DRUG$ alone.	DDI-false
DDI-DrugBank.d222.s0.p0	When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.	DDI-effect
DDI-DrugBank.d222.s0.p1	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p2	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p3	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p4	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p5	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p6	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p7	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p8	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p9	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of @DRUG$.	DDI-effect
DDI-DrugBank.d222.s1.p0	The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	DDI-advise
DDI-DrugBank.d222.s2.p0	Since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions.	DDI-advise
DDI-MedLine.d110.s0.p0	@DRUG$ (@DRUG$) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	DDI-false
DDI-MedLine.d110.s0.p1	@DRUG$ (18-MC) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	DDI-false
DDI-MedLine.d110.s0.p2	18-Methoxycoronaridine (@DRUG$) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	DDI-false
DDI-MedLine.d110.s2.p0	Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p1	Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p2	Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p3	Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p4	Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	DDI-false
DDI-MedLine.d110.s2.p5	Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p6	Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p7	Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p8	Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	DDI-false
DDI-MedLine.d110.s2.p9	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p10	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p11	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	DDI-false
DDI-MedLine.d110.s2.p12	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats; 	DDI-false
DDI-MedLine.d110.s2.p13	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats; 	DDI-false
DDI-MedLine.d110.s2.p14	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats; 	DDI-false
DDI-MedLine.d110.s3.p0	unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water). 	DDI-false
DDI-MedLine.d110.s4.p0	Both @DRUG$ and @DRUG$ ameliorate opioid withdrawal signs. 	DDI-false
DDI-MedLine.d110.s4.p1	Both @DRUG$ and 18-MC ameliorate @DRUG$ withdrawal signs. 	DDI-false
DDI-MedLine.d110.s4.p2	Both ibogaine and @DRUG$ ameliorate @DRUG$ withdrawal signs. 	DDI-false
DDI-MedLine.d110.s5.p0	Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	DDI-false
DDI-MedLine.d110.s5.p1	Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens. 	DDI-false
DDI-MedLine.d110.s5.p2	Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens. 	DDI-false
DDI-MedLine.d110.s6.p0	Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	DDI-false
DDI-MedLine.d110.s6.p1	Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens; 	DDI-effect
DDI-MedLine.d110.s6.p2	Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	DDI-effect
DDI-MedLine.d110.s6.p3	Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens; 	DDI-effect
DDI-MedLine.d110.s6.p4	Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	DDI-effect
DDI-MedLine.d110.s6.p5	Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	DDI-false
DDI-MedLine.d110.s7.p0	only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine. 	DDI-effect
DDI-MedLine.d110.s8.p0	Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants. 	DDI-false
DDI-MedLine.d110.s9.p0	@DRUG$ attenuates, but @DRUG$ potentiates, the acute locomotor effects of morphine; 	DDI-false
DDI-MedLine.d110.s9.p1	@DRUG$ attenuates, but 18-MC potentiates, the acute locomotor effects of @DRUG$; 	DDI-effect
DDI-MedLine.d110.s9.p2	Ibogaine attenuates, but @DRUG$ potentiates, the acute locomotor effects of @DRUG$; 	DDI-effect
DDI-MedLine.d110.s10.p0	both compounds attenuate @DRUG$-induced locomotion in @DRUG$-experienced rats. 	DDI-false
DDI-MedLine.d110.s13.p0	@DRUG$, but not @DRUG$, decreases heart rate at high doses. 	DDI-false
DDI-MedLine.d110.s14.p0	While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s14.p1	While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s14.p2	While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s14.p3	While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s14.p4	While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s14.p5	While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	DDI-false
DDI-MedLine.d110.s15.p0	Both @DRUG$ and @DRUG$ are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s15.p1	Both @DRUG$ and ibogaine are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s15.p2	Both @DRUG$ and ibogaine are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s15.p3	Both 18-MC and @DRUG$ are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s15.p4	Both 18-MC and @DRUG$ are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s15.p5	Both 18-MC and ibogaine are sequestered in fat and, like @DRUG$, @DRUG$ probably has an active metabolite. 	DDI-false
DDI-MedLine.d110.s16.p0	The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
DDI-MedLine.d67.s0.p0	Effect of @DRUG$ and @DRUG$ on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p1	Effect of @DRUG$ and midazolam on the antinociceptive effect of @DRUG$, metamizol and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p2	Effect of @DRUG$ and midazolam on the antinociceptive effect of morphine, @DRUG$ and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p3	Effect of @DRUG$ and midazolam on the antinociceptive effect of morphine, metamizol and @DRUG$ in mice.	DDI-false
DDI-MedLine.d67.s0.p4	Effect of diazepam and @DRUG$ on the antinociceptive effect of @DRUG$, metamizol and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p5	Effect of diazepam and @DRUG$ on the antinociceptive effect of morphine, @DRUG$ and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p6	Effect of diazepam and @DRUG$ on the antinociceptive effect of morphine, metamizol and @DRUG$ in mice.	DDI-false
DDI-MedLine.d67.s0.p7	Effect of diazepam and midazolam on the antinociceptive effect of @DRUG$, @DRUG$ and indomethacin in mice.	DDI-false
DDI-MedLine.d67.s0.p8	Effect of diazepam and midazolam on the antinociceptive effect of @DRUG$, metamizol and @DRUG$ in mice.	DDI-false
DDI-MedLine.d67.s0.p9	Effect of diazepam and midazolam on the antinociceptive effect of morphine, @DRUG$ and @DRUG$ in mice.	DDI-false
DDI-MedLine.d67.s1.p0	The influence of @DRUG$ and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p1	The influence of @DRUG$ and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p2	The influence of @DRUG$ and diazepam on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p3	The influence of @DRUG$ and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p4	The influence of midazolam and @DRUG$ on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p5	The influence of midazolam and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p6	The influence of midazolam and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p7	The influence of midazolam and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p8	The influence of midazolam and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s1.p9	The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	DDI-false
DDI-MedLine.d67.s3.p0	@DRUG$ were administered to mice 30 min before applying the @DRUG$. 	DDI-false
DDI-MedLine.d67.s5.p0	@DRUG$ at doses of 0.25 mg/kg and 2.5 mg/kg injected with @DRUG$ was found to decrease the antinociceptive effect of morphine. 	DDI-effect
DDI-MedLine.d67.s5.p1	@DRUG$ at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of @DRUG$. 	DDI-false
DDI-MedLine.d67.s5.p2	Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with @DRUG$ was found to decrease the antinociceptive effect of @DRUG$. 	DDI-false
DDI-MedLine.d67.s6.p0	Similarly, @DRUG$ decreased the antinociceptive effect of @DRUG$ (only in the tail-flick test) and indomethacin. 	DDI-effect
DDI-MedLine.d67.s6.p1	Similarly, @DRUG$ decreased the antinociceptive effect of metamizol (only in the tail-flick test) and @DRUG$. 	DDI-effect
DDI-MedLine.d67.s6.p2	Similarly, diazepam decreased the antinociceptive effect of @DRUG$ (only in the tail-flick test) and @DRUG$. 	DDI-false
DDI-MedLine.d67.s7.p0	@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, metamizol (only in the tail-flick test) and indomethacin.	DDI-effect
DDI-MedLine.d67.s7.p1	@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, @DRUG$ (only in the tail-flick test) and indomethacin.	DDI-effect
DDI-MedLine.d67.s7.p2	@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and @DRUG$.	DDI-effect
DDI-MedLine.d67.s7.p3	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, @DRUG$ (only in the tail-flick test) and indomethacin.	DDI-false
DDI-MedLine.d67.s7.p4	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, metamizol (only in the tail-flick test) and @DRUG$.	DDI-false
DDI-MedLine.d67.s7.p5	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, @DRUG$ (only in the tail-flick test) and @DRUG$.	DDI-false
DDI-DrugBank.d185.s0.p0	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/SMX).	DDI-false
DDI-DrugBank.d185.s0.p1	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/SMX).	DDI-false
DDI-DrugBank.d185.s0.p2	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/SMX).	DDI-false
DDI-DrugBank.d185.s0.p3	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/@DRUG$).	DDI-false
DDI-DrugBank.d185.s0.p4	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ (TMP/SMX).	DDI-false
DDI-DrugBank.d185.s0.p5	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (@DRUG$/SMX).	DDI-false
DDI-DrugBank.d185.s0.p6	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	DDI-false
DDI-DrugBank.d185.s0.p7	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (@DRUG$/SMX).	DDI-false
DDI-DrugBank.d185.s0.p8	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/@DRUG$).	DDI-false
DDI-DrugBank.d185.s0.p9	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/@DRUG$).	DDI-false
DDI-DrugBank.d185.s1.p0	During co-administration, systemic levels of @DRUG$ and @DRUG$ were essentially unchanged.	DDI-false
DDI-DrugBank.d185.s2.p0	Notably, systemic exposure (AUC0-12) of @DRUG$ (@DRUG$) was more than doubled in the presence of TMP/SMX.	DDI-false
DDI-DrugBank.d185.s2.p1	Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
DDI-DrugBank.d185.s2.p2	Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
DDI-DrugBank.d185.s2.p3	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
DDI-DrugBank.d185.s2.p4	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
DDI-DrugBank.d185.s2.p5	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of @DRUG$/@DRUG$.	DDI-false
DDI-DrugBank.d185.s3.p0	Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with @DRUG$/@DRUG$.	DDI-false
DDI-DrugBank.d185.s4.p0	Certain concomitant medications (such as @DRUG$, @DRUG$, St.	DDI-false
DDI-DrugBank.d185.s5.p0	John s wort) may increase the formation of @DRUG$, a metabolite of @DRUG$ associated with hemolysis.	DDI-false
DDI-DrugBank.d185.s6.p0	With oral @DRUG$ treatment, @DRUG$ such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions	DDI-effect
DDI-DrugBank.d185.s6.p1	With oral @DRUG$ treatment, folic acid antagonists such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	DDI-effect
DDI-DrugBank.d185.s6.p2	With oral dapsone treatment, @DRUG$ such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	DDI-false
DDI-DrugBank.d128.s0.p0	May interact with wthionamide (@DRUG$) and @DRUG$ (Nydrazid).	DDI-false
DDI-DrugBank.d128.s0.p1	May interact with wthionamide (@DRUG$) and isoniazid (@DRUG$).	DDI-false
DDI-DrugBank.d128.s0.p2	May interact with wthionamide (Trecator-SC) and @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d498.s0.p0	Certain @DRUG$, especially @DRUG$, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s0.p1	Certain @DRUG$, especially neomycin, @DRUG$ and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s0.p2	Certain @DRUG$, especially neomycin, streptomycin and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s0.p3	Certain antibiotics, especially @DRUG$, @DRUG$ and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s0.p4	Certain antibiotics, especially @DRUG$, streptomycin and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s0.p5	Certain antibiotics, especially neomycin, @DRUG$ and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	DDI-false
DDI-DrugBank.d498.s1.p0	These @DRUG$ should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive @DRUG$ dosage.	DDI-advise
DDI-DrugBank.d498.s2.p0	Local and some general @DRUG$, @DRUG$ and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;	DDI-false
DDI-DrugBank.d450.s0.p0	@DRUG$ are a major contributing factor to @DRUG$ toxicity.	DDI-effect
DDI-DrugBank.d450.s2.p0	@DRUG$, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p1	@DRUG$, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p2	@DRUG$, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p3	@DRUG$, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p4	@DRUG$, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p5	@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p6	@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p7	@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p8	@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p9	Quinidine, @DRUG$, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p10	Quinidine, @DRUG$, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p11	Quinidine, @DRUG$, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p12	Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p13	Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p14	Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p15	Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p16	Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p17	Quinidine, verapamil, @DRUG$, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p18	Quinidine, verapamil, @DRUG$, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p19	Quinidine, verapamil, @DRUG$, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p20	Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p21	Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p22	Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p23	Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p24	Quinidine, verapamil, amiodarone, @DRUG$, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p25	Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p26	Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p27	Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p28	Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p29	Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p30	Quinidine, verapamil, amiodarone, propafenone, @DRUG$, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p31	Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p32	Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p33	Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p34	Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p35	Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p36	Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p37	Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p38	Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p39	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p40	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p41	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p42	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s2.p43	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s2.p44	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p0	@DRUG$ and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p1	@DRUG$ and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p2	@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p3	@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s3.p4	@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p5	@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p6	Erythromycin and @DRUG$ (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p7	Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p8	Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s3.p9	Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p10	Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p11	Erythromycin and clarithromycin (and possibly other @DRUG$) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p12	Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s3.p13	Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p14	Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p15	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-mechanism
DDI-DrugBank.d450.s3.p16	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p17	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p18	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p19	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s3.p20	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	DDI-false
DDI-DrugBank.d450.s5.p0	@DRUG$ and @DRUG$, by decreasing gut motility, may increase digoxin absorption.	DDI-false
DDI-DrugBank.d450.s5.p1	@DRUG$ and diphenoxylate, by decreasing gut motility, may increase @DRUG$ absorption.	DDI-mechanism
DDI-DrugBank.d450.s5.p2	Propantheline and @DRUG$, by decreasing gut motility, may increase @DRUG$ absorption.	DDI-mechanism
DDI-DrugBank.d450.s6.p0	@DRUG$, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p1	@DRUG$, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p2	@DRUG$, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p3	@DRUG$, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p4	@DRUG$, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p5	@DRUG$, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s6.p6	Antacids, @DRUG$-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p7	Antacids, @DRUG$-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p8	Antacids, @DRUG$-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p9	Antacids, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p10	Antacids, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s6.p11	Antacids, kaolin-pectin, @DRUG$, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p12	Antacids, kaolin-pectin, @DRUG$, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p13	Antacids, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p14	Antacids, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s6.p15	Antacids, kaolin-pectin, sulfasalazine, @DRUG$, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p16	Antacids, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p17	Antacids, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s6.p18	Antacids, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	DDI-false
DDI-DrugBank.d450.s6.p19	Antacids, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s6.p20	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	DDI-mechanism
DDI-DrugBank.d450.s7.p0	@DRUG$ may decrease serum @DRUG$ concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.	DDI-mechanism
DDI-DrugBank.d450.s7.p1	@DRUG$ may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of @DRUG$.	DDI-false
DDI-DrugBank.d450.s7.p2	Rifampin may decrease serum @DRUG$ concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of @DRUG$.	DDI-false
DDI-DrugBank.d450.s8.p0	There have been inconsistent reports regarding the effects of other drugs (e.g., @DRUG$, @DRUG$) on serum digoxin concentration.	DDI-false
DDI-DrugBank.d450.s8.p1	There have been inconsistent reports regarding the effects of other drugs (e.g., @DRUG$, penicillamine) on serum @DRUG$ concentration.	DDI-false
DDI-DrugBank.d450.s8.p2	There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, @DRUG$) on serum @DRUG$ concentration.	DDI-false
DDI-DrugBank.d450.s9.p0	@DRUG$ administration to a digitalized, hypothyroid patient may increase the dose requirement of @DRUG$.	DDI-advise
DDI-DrugBank.d450.s10.p0	Concomitant use of @DRUG$ and @DRUG$ increases the risk of cardiac arrhythmias.	DDI-effect
DDI-DrugBank.d450.s12.p0	Although @DRUG$ or @DRUG$ and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	DDI-false
DDI-DrugBank.d450.s12.p1	Although @DRUG$ or calcium channel blockers and @DRUG$ may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	DDI-effect
DDI-DrugBank.d450.s12.p2	Although beta-adrenergic blockers or @DRUG$ and @DRUG$ may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	DDI-effect
DDI-DrugBank.d450.s14.p0	Furthermore, caution should be exercised when combining @DRUG$ with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of @DRUG$.	DDI-false
DDI-DrugBank.d494.s0.p0	Concomitant use with other @DRUG$-containing medicines (including @DRUG$) may cause too much calcium in the blood or urine, which may increase the chance of side effects.	DDI-false
DDI-DrugBank.d494.s0.p1	Concomitant use with other @DRUG$-containing medicines (including antacids) may cause too much @DRUG$ in the blood or urine, which may increase the chance of side effects.	DDI-false
DDI-DrugBank.d494.s0.p2	Concomitant use with other calcium-containing medicines (including @DRUG$) may cause too much @DRUG$ in the blood or urine, which may increase the chance of side effects.	DDI-false
DDI-DrugBank.d494.s1.p0	Using @DRUG$ with @DRUG$ (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.	DDI-effect
DDI-DrugBank.d494.s1.p1	Using @DRUG$ with digitalis glycosides (heart medicine) may cause hypercalcemia (too much @DRUG$ in the blood), which could increase the chance of developing an irregular heartbeat.	DDI-false
DDI-DrugBank.d494.s1.p2	Using calcium acetate with @DRUG$ (heart medicine) may cause hypercalcemia (too much @DRUG$ in the blood), which could increase the chance of developing an irregular heartbeat.	DDI-false
DDI-DrugBank.d563.s0.p0	Special consideration should be given to the administration of @DRUG$ in patients receiving @DRUG$ or other drugs that could cause or potentiate hypotension.	DDI-advise
DDI-DrugBank.d39.s0.p0	Persons taking most @DRUG$, @DRUG$ and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p1	Persons taking most @DRUG$, methotrexate and @DRUG$ invalidate folic acid and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p2	Persons taking most @DRUG$, methotrexate and pyrimethamine invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p3	Persons taking most @DRUG$, methotrexate and pyrimethamine invalidate folic acid and @DRUG$ diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p4	Persons taking most antibiotics, @DRUG$ and @DRUG$ invalidate folic acid and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p5	Persons taking most antibiotics, @DRUG$ and pyrimethamine invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p6	Persons taking most antibiotics, @DRUG$ and pyrimethamine invalidate folic acid and @DRUG$ diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p7	Persons taking most antibiotics, methotrexate and @DRUG$ invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p8	Persons taking most antibiotics, methotrexate and @DRUG$ invalidate folic acid and @DRUG$ diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s0.p9	Persons taking most antibiotics, methotrexate and pyrimethamine invalidate @DRUG$ and @DRUG$ diagnostic blood assays.	DDI-false
DDI-DrugBank.d39.s1.p0	@DRUG$ @DRUG$ and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.	DDI-false
DDI-DrugBank.d39.s1.p1	@DRUG$ para-aminosalicylic acid and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of vitamin B12.	DDI-false
DDI-DrugBank.d39.s1.p2	@DRUG$ para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of @DRUG$.	DDI-mechanism
DDI-DrugBank.d39.s1.p3	Colchicine @DRUG$ and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of vitamin B12.	DDI-false
DDI-DrugBank.d39.s1.p4	Colchicine @DRUG$ and heavy alcohol intake for longer than 2 weeks may produce malabsorption of @DRUG$.	DDI-mechanism
DDI-DrugBank.d39.s1.p5	Colchicine para-aminosalicylic acid and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of @DRUG$.	DDI-mechanism
DDI-MedLine.d68.s0.p0	[The effect of @DRUG$ on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p1	[The effect of @DRUG$ on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p2	[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p3	[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p4	[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p5	[The effect of cimetidine on the renal excretion of @DRUG$ and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p6	[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p7	[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p8	[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p9	[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p10	[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p11	[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s0.p12	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	DDI-mechanism
DDI-MedLine.d68.s0.p13	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	DDI-mechanism
DDI-MedLine.d68.s0.p14	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and i@DRUG$excretion in chronic canine experiments. 	DDI-false
DDI-MedLine.d68.s1.p0	The higher @DRUG$ and @DRUG$ excretion was due to their increased renal tubular secretion. 	DDI-false
DDI-MedLine.d68.s2.p0	In dogs, @DRUG$ unchanged the secretion of @DRUG$, a test agent for anionic transport. 	DDI-false
DDI-MedLine.d68.s3.p0	Possible extrarenal mechanisms of action of @DRUG$ on @DRUG$ and iodamide transport were also examined.	DDI-false
DDI-MedLine.d68.s3.p1	Possible extrarenal mechanisms of action of @DRUG$ on verografine and @DRUG$ transport were also examined.	DDI-false
DDI-MedLine.d68.s3.p2	Possible extrarenal mechanisms of action of cimetidine on @DRUG$ and @DRUG$ transport were also examined.	DDI-false
DDI-DrugBank.d70.s11.p0	The potential effects of @DRUG$ on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days @DRUG$ showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.	DDI-false
DDI-MedLine.d42.s4.p0	METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, Viagra, and erectile dysfunction. 	DDI-false
DDI-MedLine.d42.s4.p1	METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, @DRUG$, and erectile dysfunction. 	DDI-false
DDI-MedLine.d42.s4.p2	METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, @DRUG$, and erectile dysfunction. 	DDI-false
DDI-MedLine.d42.s5.p0	RESULTS: @DRUG$ has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, @DRUG$ [SSRIs]). 	DDI-false
DDI-MedLine.d42.s5.p1	RESULTS: @DRUG$ has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [@DRUG$]). 	DDI-false
DDI-MedLine.d42.s5.p2	RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, @DRUG$ [@DRUG$]). 	DDI-false
DDI-MedLine.d42.s9.p0	however, patients with moderate to severe cardiovascular disease or those taking @DRUG$ therapy are at increased risk for potentially serious cardiovascular adverse effects with @DRUG$ therapy. 	DDI-effect
DDI-MedLine.d42.s10.p0	In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes @DRUG$, may experience increased drug concentrations and possible toxicity from normal doses of @DRUG$. 	DDI-false
DDI-DrugBank.d240.s0.p0	@DRUG$ may interact with @DRUG$ or other CNS depressants, causing increased sedative effects.	DDI-effect
DDI-DrugBank.d240.s0.p1	@DRUG$ may interact with alcohol or other @DRUG$, causing increased sedative effects.	DDI-effect
DDI-DrugBank.d240.s0.p2	Ethopropazine may interact with @DRUG$ or other @DRUG$, causing increased sedative effects.	DDI-false
DDI-DrugBank.d240.s1.p0	It may also interact with @DRUG$ or other @DRUG$ or MAOIs, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d240.s1.p1	It may also interact with @DRUG$ or other anticholinergic drugs or @DRUG$, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d240.s1.p2	It may also interact with amantadine or other @DRUG$ or @DRUG$, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d240.s2.p0	@DRUG$ can interact with @DRUG$, increasing the metabolism of chlorpromazine.	DDI-mechanism
DDI-DrugBank.d240.s2.p1	@DRUG$ can interact with chlorpromazine, increasing the metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d240.s2.p2	Ethopropazine can interact with @DRUG$, increasing the metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d529.s0.p0	@DRUG$: Administration of @DRUG$ to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s0.p1	@DRUG$: Administration of flurbiprofen to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s0.p2	@DRUG$: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s0.p3	Antacids: Administration of @DRUG$ to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s0.p4	Antacids: Administration of @DRUG$ to volunteers under fasting conditions, or with antacid suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s0.p5	Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	DDI-false
DDI-DrugBank.d529.s2.p0	@DRUG$: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p1	@DRUG$: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p2	@DRUG$: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p3	Anticoagulants: @DRUG$ like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p4	Anticoagulants: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-effect
DDI-DrugBank.d529.s2.p5	Anticoagulants: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-effect
DDI-DrugBank.d529.s3.p0	The physician should be cautious when administering @DRUG$ to patients taking @DRUG$.	DDI-advise
DDI-DrugBank.d529.s4.p0	@DRUG$: Concurrent administration of @DRUG$ and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.	DDI-false
DDI-DrugBank.d529.s4.p1	@DRUG$: Concurrent administration of aspirin and @DRUG$ resulted in 50% lower serum flurbiprofen concentrations.	DDI-false
DDI-DrugBank.d529.s4.p2	@DRUG$: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d529.s4.p3	Aspirin: Concurrent administration of @DRUG$ and @DRUG$ resulted in 50% lower serum flurbiprofen concentrations.	DDI-mechanism
DDI-DrugBank.d529.s4.p4	Aspirin: Concurrent administration of @DRUG$ and flurbiprofen resulted in 50% lower serum @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d529.s4.p5	Aspirin: Concurrent administration of aspirin and @DRUG$ resulted in 50% lower serum @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d529.s5.p0	This effect of @DRUG$ (which also lowers serum concentrations of other @DRUG$ given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).	DDI-false
DDI-DrugBank.d529.s6.p0	Concurrent use of @DRUG$ and @DRUG$ is therefore not recommended.	DDI-advise
DDI-DrugBank.d529.s7.p0	@DRUG$: The effect of @DRUG$ on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p1	@DRUG$: The effect of flurbiprofen on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p2	@DRUG$: The effect of flurbiprofen on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p3	Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p4	Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p5	Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to @DRUG$ and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s8.p0	@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not atenolol.	DDI-effect
DDI-DrugBank.d529.s8.p1	@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of propranolol but not @DRUG$.	DDI-false
DDI-DrugBank.d529.s8.p2	Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not @DRUG$.	DDI-false
DDI-DrugBank.d529.s10.p0	@DRUG$ did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with @DRUG$s hypotensive effect is unknown.	DDI-int
DDI-DrugBank.d529.s11.p0	Patients taking both @DRUG$ and a @DRUG$ should be monitored to ensure that a satisfactory hypotensive effect is achieved.	DDI-advise
DDI-DrugBank.d529.s12.p0	@DRUG$, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p1	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p2	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p3	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p4	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p5	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p6	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p7	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p8	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p9	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p10	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p11	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p12	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p13	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p14	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p15	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p16	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p17	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p18	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p19	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p20	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with @DRUG$.	DDI-mechanism
DDI-DrugBank.d529.s13.p0	@DRUG$: Studies of concomitant administration of @DRUG$ and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	DDI-false
DDI-DrugBank.d529.s13.p1	@DRUG$: Studies of concomitant administration of flurbiprofen and @DRUG$ to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	DDI-false
DDI-DrugBank.d529.s13.p2	Digoxin: Studies of concomitant administration of @DRUG$ and @DRUG$ to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	DDI-false
DDI-DrugBank.d529.s14.p0	@DRUG$: Studies in normal volunteers have shown that @DRUG$ like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.	DDI-false
DDI-DrugBank.d529.s14.p1	@DRUG$: Studies in normal volunteers have shown that flurbiprofen like other @DRUG$, can interfere with the effects of furosemide.	DDI-false
DDI-DrugBank.d529.s14.p2	@DRUG$: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of @DRUG$.	DDI-false
DDI-DrugBank.d529.s14.p3	Diuretics: Studies in normal volunteers have shown that @DRUG$ like other @DRUG$, can interfere with the effects of furosemide.	DDI-false
DDI-DrugBank.d529.s14.p4	Diuretics: Studies in normal volunteers have shown that @DRUG$ like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d529.s14.p5	Diuretics: Studies in normal volunteers have shown that flurbiprofen like other @DRUG$, can interfere with the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d529.s16.p0	Other @DRUG$ that inhibit prostaglandin synthesis have been shown to interfere with @DRUG$ in some studies and with potassium-sparing diuretics.	DDI-effect
DDI-DrugBank.d529.s16.p1	Other @DRUG$ that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with @DRUG$.	DDI-effect
DDI-DrugBank.d529.s16.p2	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with @DRUG$ in some studies and with @DRUG$.	DDI-false
DDI-DrugBank.d529.s17.p0	Patients receiving @DRUG$ and @DRUG$ or other diuretics should be observed closely to determine if the desired effect is obtained.	DDI-advise
DDI-DrugBank.d529.s17.p1	Patients receiving @DRUG$ and furosemide or other @DRUG$ should be observed closely to determine if the desired effect is obtained.	DDI-advise
DDI-DrugBank.d529.s17.p2	Patients receiving flurbiprofen and @DRUG$ or other @DRUG$ should be observed closely to determine if the desired effect is obtained.	DDI-false
DDI-DrugBank.d529.s18.p0	Oral @DRUG$: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p1	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p2	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p3	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p4	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p5	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p6	Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p7	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p8	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p9	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p10	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p11	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p12	Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p13	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p14	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p15	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p16	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p17	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p18	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p19	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p20	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p21	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p22	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p23	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p24	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p25	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or @DRUG$ with phenformin (n=6).	DDI-false
DDI-DrugBank.d529.s18.p26	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s18.p27	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with @DRUG$ (n=6).	DDI-false
DDI-DrugBank.d529.s19.p0	Although there was a slight reduction in blood sugar concentrations during concomitant administration of @DRUG$ and @DRUG$, there were no signs or symptoms of hypoglycemia.	DDI-effect
DDI-DrugBank.d57.s0.p0	In vitro mixing of an @DRUG$ with beta-lactamtype @DRUG$ (penicillins or cephalosporins) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p1	In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p2	In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (penicillins or @DRUG$) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p3	In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d57.s0.p4	In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (penicillins or @DRUG$) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d57.s0.p5	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (@DRUG$ or @DRUG$) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d57.s1.p0	Even when an @DRUG$ and a @DRUG$-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	DDI-mechanism
DDI-DrugBank.d57.s1.p1	Even when an @DRUG$ and a penicillin-type drug are administered separately by different routes, a reduction in @DRUG$ serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	DDI-false
DDI-DrugBank.d57.s1.p2	Even when an aminoglycoside and a @DRUG$-type drug are administered separately by different routes, a reduction in @DRUG$ serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	DDI-false
DDI-DrugBank.d327.s0.p0	There have been isolated reports of patients experiencing increases in their prothrombin times when @DRUG$ was added to @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d427.s0.p0	Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	DDI-mechanism
DDI-DrugBank.d427.s1.p0	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	DDI-false
DDI-DrugBank.d427.s1.p1	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with quinolones and @DRUG$.	DDI-false
DDI-DrugBank.d427.s1.p2	There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d427.s2.p0	Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted, as required.	DDI-false
DDI-DrugBank.d427.s3.p0	@DRUG$ have been shown to interfere with the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d427.s5.p0	@DRUG$, including @DRUG$, may enhance the effects of the oral anticoagulant warfarin or its derivatives.	DDI-false
DDI-DrugBank.d427.s5.p1	@DRUG$, including nalidixic acid, may enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
DDI-DrugBank.d427.s5.p2	@DRUG$, including nalidixic acid, may enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
DDI-DrugBank.d427.s5.p3	Quinolones, including @DRUG$, may enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
DDI-DrugBank.d427.s5.p4	Quinolones, including @DRUG$, may enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
DDI-DrugBank.d427.s5.p5	Quinolones, including nalidixic acid, may enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	DDI-false
DDI-DrugBank.d427.s7.p0	@DRUG$ interferes with the therapeutic action of @DRUG$.	DDI-effect
DDI-DrugBank.d427.s8.p0	@DRUG$ containing @DRUG$, aluminum, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p1	@DRUG$ containing magnesium, @DRUG$, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p2	@DRUG$ containing magnesium, aluminum, or @DRUG$;	DDI-false
DDI-DrugBank.d427.s8.p3	Antacids containing @DRUG$, @DRUG$, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p4	Antacids containing @DRUG$, aluminum, or @DRUG$;	DDI-false
DDI-DrugBank.d427.s8.p5	Antacids containing magnesium, @DRUG$, or @DRUG$;	DDI-false
DDI-DrugBank.d427.s9.p0	@DRUG$ or divalent or trivalent cations such as @DRUG$;	DDI-false
DDI-DrugBank.d427.s10.p0	@DRUG$ containing @DRUG$;	DDI-false
DDI-DrugBank.d427.s11.p0	and @DRUG$ , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.	DDI-false
DDI-DrugBank.d427.s11.p1	and @DRUG$ , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d427.s11.p2	and Videx , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d427.s13.p0	Elevated serum levels of @DRUG$ have been reported with the concomitant use of some @DRUG$ and cyclosporine.	DDI-false
DDI-DrugBank.d427.s13.p1	Elevated serum levels of @DRUG$ have been reported with the concomitant use of some quinolones and @DRUG$.	DDI-false
DDI-DrugBank.d427.s13.p2	Elevated serum levels of cyclosporine have been reported with the concomitant use of some @DRUG$ and @DRUG$.	DDI-mechanism
DDI-DrugBank.d427.s14.p0	Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	DDI-false
DDI-DrugBank.d55.s0.p0	@DRUG$ injection and @DRUG$ should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.	DDI-advise
DDI-DrugBank.d55.s2.p0	@DRUG$ should be used with caution, if at all, when potent inhalational @DRUG$ such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	DDI-advise
DDI-DrugBank.d55.s2.p1	@DRUG$ should be used with caution, if at all, when potent inhalational anesthetics such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	DDI-advise
DDI-DrugBank.d55.s2.p2	@DRUG$ should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of @DRUG$.	DDI-false
DDI-DrugBank.d55.s2.p3	ISUPREL should be used with caution, if at all, when potent inhalational @DRUG$ such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	DDI-false
DDI-DrugBank.d55.s2.p4	ISUPREL should be used with caution, if at all, when potent inhalational @DRUG$ such as halothane are employed because of potential to sensitize the myocardium to effects of @DRUG$.	DDI-false
DDI-DrugBank.d55.s2.p5	ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of @DRUG$.	DDI-false
DDI-MedLine.d134.s0.p0	[Dose-time effects of competitive displacement of @DRUG$ by @DRUG$ following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s0.p1	[Dose-time effects of competitive displacement of @DRUG$ by sodium perchlorate following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s0.p2	[Dose-time effects of competitive displacement of @DRUG$ by sodium perchlorate following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s0.p3	[Dose-time effects of competitive displacement of radiopertechnetate by @DRUG$ following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s0.p4	[Dose-time effects of competitive displacement of radiopertechnetate by @DRUG$ following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s0.p5	[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	DDI-false
DDI-MedLine.d134.s1.p0	An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	DDI-false
DDI-MedLine.d134.s1.p1	An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$. 	DDI-false
DDI-MedLine.d134.s1.p2	An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$. 	DDI-false
DDI-MedLine.d134.s2.p0	An intravenous injection of @DRUG$ given later also produces a complete and immediately beginning depletion of @DRUG$ already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 	DDI-mechanism
DDI-DrugBank.d469.s0.p0	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: @DRUG$;	DDI-effect
DDI-DrugBank.d469.s3.p0	certain @DRUG$, especially the @DRUG$ and polymyxins;	DDI-false
DDI-DrugBank.d469.s3.p1	certain @DRUG$, especially the aminoglycosides and @DRUG$;	DDI-false
DDI-DrugBank.d469.s3.p2	certain antibiotics, especially the @DRUG$ and @DRUG$;	DDI-false
DDI-DrugBank.d469.s7.p0	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p1	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p2	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p3	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p4	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p5	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p6	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p7	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p8	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-effect
DDI-DrugBank.d469.s7.p9	Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-effect
DDI-DrugBank.d469.s7.p10	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p11	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p12	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p13	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p14	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p15	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p16	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p17	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p18	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p19	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p20	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p21	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p22	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p23	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p24	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p25	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p26	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p27	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p28	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p29	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p30	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p31	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p32	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p33	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p34	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p35	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p36	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p37	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p38	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p39	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p40	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p41	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p42	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p43	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p44	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p45	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;@DRUG$;magnesium salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p46	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p47	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p48	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p49	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;@DRUG$ salts;procainamide;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p50	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p51	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p52	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;@DRUG$;and quinidine.	DDI-false
DDI-DrugBank.d469.s7.p53	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s7.p54	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and @DRUG$.	DDI-false
DDI-DrugBank.d469.s9.p0	The prior administration of @DRUG$ does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by @DRUG$.	DDI-effect
DDI-DrugBank.d469.s10.p0	@DRUG$ should not be administered until a patient has recovered from @DRUG$-induced neuromuscular block.	DDI-advise
DDI-DrugBank.d348.s0.p0	Although the pressor activity of @DRUG$ is very low compared to its antidiuretic activity, large doses of @DRUG$ Tablets should be used with other pressor agents only with careful patient monitoring.	DDI-false
DDI-DrugBank.d516.s0.p0	@DRUG$: In three pharmacokinetic studies including 46 normal, healthy subjects, @DRUG$ clearance and concentration were not significantly altered by the addition of lomefloxacin.	DDI-false
DDI-DrugBank.d516.s0.p1	@DRUG$: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of @DRUG$.	DDI-false
DDI-DrugBank.d516.s0.p2	Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, @DRUG$ clearance and concentration were not significantly altered by the addition of @DRUG$.	DDI-false
DDI-DrugBank.d516.s1.p0	In clinical studies where patients were on chronic @DRUG$ therapy, @DRUG$ had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.	DDI-false
DDI-DrugBank.d516.s1.p1	In clinical studies where patients were on chronic @DRUG$ therapy, lomefloxacin had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of theophylline clearance.	DDI-false
DDI-DrugBank.d516.s1.p2	In clinical studies where patients were on chronic @DRUG$ therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of @DRUG$ clearance.	DDI-false
DDI-DrugBank.d516.s1.p3	In clinical studies where patients were on chronic theophylline therapy, @DRUG$ had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of theophylline clearance.	DDI-false
DDI-DrugBank.d516.s1.p4	In clinical studies where patients were on chronic theophylline therapy, @DRUG$ had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of @DRUG$ clearance.	DDI-false
DDI-DrugBank.d516.s1.p5	In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of @DRUG$ clearance.	DDI-false
DDI-DrugBank.d516.s3.p0	@DRUG$ and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p1	@DRUG$ and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p2	@DRUG$ and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p3	@DRUG$ and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p4	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p5	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p6	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p7	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p8	Antacids and @DRUG$: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p9	Antacids and @DRUG$: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p10	Antacids and @DRUG$: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p11	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p12	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p13	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p14	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p15	Antacids and sucralfate: @DRUG$ and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p16	Antacids and sucralfate: @DRUG$ and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p17	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p18	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p19	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p20	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p21	Antacids and sucralfate: Sucralfate and @DRUG$ containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p22	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p23	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p24	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p25	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p26	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p27	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p28	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p29	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p30	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p31	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p32	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p33	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p34	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p35	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s4.p0	@DRUG$ administered 2 hours before @DRUG$ resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).	DDI-mechanism
DDI-DrugBank.d516.s5.p0	@DRUG$- and @DRUG$-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-false
DDI-DrugBank.d516.s5.p1	@DRUG$- and aluminum-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-false
DDI-DrugBank.d516.s5.p2	@DRUG$- and aluminum-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-mechanism
DDI-DrugBank.d516.s5.p3	@DRUG$- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	DDI-false
DDI-DrugBank.d516.s5.p4	Magnesium- and @DRUG$-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-false
DDI-DrugBank.d516.s5.p5	Magnesium- and @DRUG$-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-mechanism
DDI-DrugBank.d516.s5.p6	Magnesium- and @DRUG$-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	DDI-false
DDI-DrugBank.d516.s5.p7	Magnesium- and aluminum-containing @DRUG$, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	DDI-mechanism
DDI-DrugBank.d516.s5.p8	Magnesium- and aluminum-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	DDI-false
DDI-DrugBank.d516.s5.p9	Magnesium- and aluminum-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of @DRUG$.	DDI-false
DDI-DrugBank.d516.s6.p0	Separating the doses of @DRUG$ and @DRUG$ minimizes this decrease in bioavailability;	DDI-mechanism
DDI-DrugBank.d516.s7.p0	therefore, administration of these agents should precede @DRUG$ dosing by 4 hours or follow @DRUG$ dosing by at least 2 hours.	DDI-false
DDI-DrugBank.d516.s8.p0	@DRUG$: Two hundred mg of @DRUG$ (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.	DDI-false
DDI-DrugBank.d516.s8.p1	@DRUG$: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of @DRUG$ after being dosed at 400 mg qd.	DDI-false
DDI-DrugBank.d516.s8.p2	Caffeine: Two hundred mg of @DRUG$ (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of @DRUG$ after being dosed at 400 mg qd.	DDI-false
DDI-DrugBank.d516.s9.p0	This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either @DRUG$ or its major metabolite, @DRUG$.	DDI-false
DDI-DrugBank.d516.s11.p0	Other @DRUG$ have demonstrated moderate to marked interference with the metabolism of @DRUG$, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.	DDI-mechanism
DDI-DrugBank.d516.s11.p1	Other @DRUG$ have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of @DRUG$.	DDI-false
DDI-DrugBank.d516.s11.p2	Other quinolones have demonstrated moderate to marked interference with the metabolism of @DRUG$, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of @DRUG$.	DDI-false
DDI-DrugBank.d516.s12.p0	@DRUG$: @DRUG$ has been demonstrated to interfere with the elimination of other quinolones.	DDI-false
DDI-DrugBank.d516.s12.p1	@DRUG$: Cimetidine has been demonstrated to interfere with the elimination of other @DRUG$.	DDI-false
DDI-DrugBank.d516.s12.p2	Cimetidine: @DRUG$ has been demonstrated to interfere with the elimination of other @DRUG$.	DDI-mechanism
DDI-DrugBank.d516.s14.p0	The interaction between @DRUG$ and @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d516.s15.p0	@DRUG$: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the quinolone class.	DDI-false
DDI-DrugBank.d516.s15.p1	@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	DDI-false
DDI-DrugBank.d516.s15.p2	@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	DDI-false
DDI-DrugBank.d516.s15.p3	Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	DDI-false
DDI-DrugBank.d516.s15.p4	Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	DDI-false
DDI-DrugBank.d516.s15.p5	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the @DRUG$.	DDI-mechanism
DDI-DrugBank.d516.s16.p0	Interaction between @DRUG$ and @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d516.s17.p0	@DRUG$: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s17.p1	@DRUG$: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s17.p2	@DRUG$: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s17.p3	Omeprazole: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s17.p4	Omeprazole: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s17.p5	Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	DDI-false
DDI-DrugBank.d516.s19.p0	@DRUG$: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s19.p1	@DRUG$: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s19.p2	@DRUG$: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s19.p3	Phenytoin: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s19.p4	Phenytoin: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s19.p5	Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	DDI-false
DDI-DrugBank.d516.s20.p0	@DRUG$ is unlikely to have a significant effect on @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d516.s21.p0	@DRUG$: @DRUG$ slows the renal elimination of lome-floxacin.	DDI-false
DDI-DrugBank.d516.s23.p0	@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p1	@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p2	@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p3	@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p4	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p5	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p6	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p7	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p8	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s23.p9	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and @DRUG$ at steady-state in 28 healthy males.	DDI-false
DDI-DrugBank.d516.s24.p0	@DRUG$: @DRUG$ may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.	DDI-false
DDI-DrugBank.d516.s24.p1	@DRUG$: Quinolones may enhance the effects of the oral @DRUG$, warfarin, or its derivatives.	DDI-false
DDI-DrugBank.d516.s24.p2	@DRUG$: Quinolones may enhance the effects of the oral anticoagulant, @DRUG$, or its derivatives.	DDI-false
DDI-DrugBank.d516.s24.p3	Warfarin: @DRUG$ may enhance the effects of the oral @DRUG$, warfarin, or its derivatives.	DDI-effect
DDI-DrugBank.d516.s24.p4	Warfarin: @DRUG$ may enhance the effects of the oral anticoagulant, @DRUG$, or its derivatives.	DDI-effect
DDI-DrugBank.d516.s24.p5	Warfarin: Quinolones may enhance the effects of the oral @DRUG$, @DRUG$, or its derivatives.	DDI-false
DDI-DrugBank.d516.s26.p0	However, no clinically or statistically significant differences in prothrombin time ratio or @DRUG$ enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both @DRUG$ and lomefloxacin under steady-state conditions.	DDI-false
DDI-DrugBank.d516.s26.p1	However, no clinically or statistically significant differences in prothrombin time ratio or @DRUG$ enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and @DRUG$ under steady-state conditions.	DDI-false
DDI-DrugBank.d516.s26.p2	However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both @DRUG$ and @DRUG$ under steady-state conditions.	DDI-false
DDI-DrugBank.d309.s0.p0	Additive CNS depression may occur when @DRUG$ are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and alcohol.	DDI-effect
DDI-DrugBank.d309.s0.p1	Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and alcohol.	DDI-effect
DDI-DrugBank.d309.s0.p2	Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and alcohol.	DDI-effect
DDI-DrugBank.d309.s0.p3	Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and @DRUG$.	DDI-effect
DDI-DrugBank.d309.s0.p4	Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including @DRUG$, tranquilizers, and alcohol.	DDI-false
DDI-DrugBank.d309.s0.p5	Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d309.s0.p6	Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and @DRUG$.	DDI-false
DDI-DrugBank.d309.s0.p7	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d309.s0.p8	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and @DRUG$.	DDI-false
DDI-DrugBank.d309.s0.p9	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d309.s1.p0	Patients receiving @DRUG$ should be advised against the concurrent use of other @DRUG$.	DDI-advise
DDI-DrugBank.d309.s2.p0	@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.	DDI-effect
DDI-DrugBank.d232.s0.p0	After multiple dosing, @DRUG$ (@DRUG$  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.	DDI-false
DDI-DrugBank.d232.s0.p1	After multiple dosing, @DRUG$ (AVONEX  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
DDI-DrugBank.d232.s0.p2	After multiple dosing, interferon beta-1a (@DRUG$  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
DDI-DrugBank.d232.s1.p0	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s1.p1	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s1.p2	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s1.p3	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s1.p4	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s1.p5	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
DDI-DrugBank.d232.s2.p0	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p1	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p2	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p3	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p4	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
DDI-DrugBank.d232.s2.p5	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p6	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p7	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p8	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
DDI-DrugBank.d232.s2.p9	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p10	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p11	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
DDI-DrugBank.d232.s2.p12	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
DDI-DrugBank.d232.s2.p13	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
DDI-DrugBank.d232.s2.p14	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d148.s0.p0	@DRUG$: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p1	@DRUG$: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p2	@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p3	@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p4	Heparin: Since @DRUG$ is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p5	Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p6	Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p7	Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p8	Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p9	Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s1.p0	However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	DDI-false
DDI-DrugBank.d148.s1.p1	However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
DDI-DrugBank.d148.s1.p2	However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
DDI-DrugBank.d148.s2.p0	@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p1	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p2	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p3	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p4	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p5	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p6	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p7	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p8	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p9	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p10	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p11	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p12	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p13	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p14	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p15	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p16	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p17	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p18	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p19	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s2.p20	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
DDI-DrugBank.d148.s3.p0	Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	DDI-false
DDI-DrugBank.d148.s3.p1	Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
DDI-DrugBank.d148.s3.p2	Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
DDI-DrugBank.d148.s4.p0	However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	DDI-effect
DDI-DrugBank.d148.s5.p0	@DRUG$: The safety and effectiveness of @DRUG$ with thrombolytic agents have not been established.	DDI-false
DDI-DrugBank.d148.s5.p1	@DRUG$: The safety and effectiveness of Argatroban with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d148.s5.p2	Thrombolytic agents: The safety and effectiveness of @DRUG$ with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d148.s6.p0	Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	DDI-effect
DDI-DrugBank.d148.s6.p1	Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-effect
DDI-DrugBank.d148.s6.p2	Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-effect
DDI-DrugBank.d148.s6.p3	Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-false
DDI-DrugBank.d148.s6.p4	Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-false
DDI-DrugBank.d148.s6.p5	Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	DDI-false
DDI-DrugBank.d148.s7.p0	Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	DDI-false
DDI-DrugBank.d148.s7.p1	Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
DDI-DrugBank.d148.s7.p2	Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
DDI-MedLine.d23.s0.p0	The effects of @DRUG$ and of @DRUG$ anesthesia on digitalis tolerance in dogs.  	DDI-false
DDI-MedLine.d23.s0.p1	The effects of @DRUG$ and of Innovar anesthesia on @DRUG$ tolerance in dogs.  	DDI-false
DDI-MedLine.d23.s0.p2	The effects of ketamine and of @DRUG$ anesthesia on @DRUG$ tolerance in dogs.  	DDI-false
DDI-MedLine.d23.s1.p0	In a comparison of @DRUG$ tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p1	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p2	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p3	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p4	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p5	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p6	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p7	In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p8	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p9	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p10	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-effect
DDI-MedLine.d23.s1.p11	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p12	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p13	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p14	In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p15	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p16	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-effect
DDI-MedLine.d23.s1.p17	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p18	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p19	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p20	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p21	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	DDI-effect
DDI-MedLine.d23.s1.p22	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p23	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p24	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p25	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p26	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p27	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p28	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p29	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p30	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with @DRUG$ or Innovar than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p31	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p32	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p33	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or @DRUG$ than with pentobarbital. 	DDI-false
DDI-MedLine.d23.s1.p34	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s1.p35	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with @DRUG$. 	DDI-false
DDI-MedLine.d23.s2.p0	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p1	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p2	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p3	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p4	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p5	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p6	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p7	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p8	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p9	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p10	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p11	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p12	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p13	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p14	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after @DRUG$.	DDI-false
DDI-MedLine.d131.s0.p0	Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.  	DDI-effect
DDI-MedLine.d131.s0.p1	Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.  	DDI-effect
DDI-MedLine.d131.s0.p2	Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.  	DDI-false
DDI-MedLine.d131.s1.p0	The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s1.p1	The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s1.p2	The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s1.p3	The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s1.p4	The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s1.p5	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	DDI-false
DDI-MedLine.d131.s3.p0	It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue. 	DDI-effect
DDI-MedLine.d131.s4.p0	On the contrary, @DRUG$ and @DRUG$ were agonists in induction of analgesia. 	DDI-effect
DDI-MedLine.d131.s5.p0	It is concluded that @DRUG$ modulates in an opposite way the function of the enkephalinergic neurons and the central action of @DRUG$.	DDI-effect
DDI-DrugBank.d453.s0.p0	@DRUG$, a @DRUG$, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.	DDI-false
DDI-DrugBank.d453.s0.p1	@DRUG$, a cytostatic agent, has been reported to inactivate the antifungal activity of @DRUG$ by competitive inhibition.	DDI-effect
DDI-DrugBank.d453.s0.p2	Cytosine arabinoside, a @DRUG$, has been reported to inactivate the antifungal activity of @DRUG$ by competitive inhibition.	DDI-false
DDI-DrugBank.d158.s0.p0	Urinary acidifying agents These agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
DDI-DrugBank.d158.s0.p1	Urinary acidifying agents These agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
DDI-DrugBank.d158.s0.p2	Urinary acidifying agents These agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
DDI-DrugBank.d158.s2.p0	@DRUG$ @DRUG$ are inhibited by amphetamines.	DDI-false
DDI-DrugBank.d158.s2.p1	@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	DDI-false
DDI-DrugBank.d158.s2.p2	Adrenergic blockers @DRUG$ are inhibited by @DRUG$.	DDI-effect
DDI-DrugBank.d158.s3.p0	@DRUG$, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
DDI-DrugBank.d158.s3.p1	@DRUG$, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
DDI-DrugBank.d158.s3.p2	@DRUG$, tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
DDI-DrugBank.d158.s3.p3	@DRUG$, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
DDI-DrugBank.d158.s3.p4	Antidepressants, @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
DDI-DrugBank.d158.s3.p5	Antidepressants, @DRUG$ Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
DDI-DrugBank.d158.s3.p6	Antidepressants, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
DDI-DrugBank.d158.s3.p7	Antidepressants, tricyclic @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-effect
DDI-DrugBank.d158.s3.p8	Antidepressants, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-effect
DDI-DrugBank.d158.s3.p9	Antidepressants, tricyclic Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	DDI-false
DDI-DrugBank.d158.s4.p0	@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p1	@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p2	@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p3	@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p4	d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p5	d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p6	d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p7	d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p8	d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p9	d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s6.p0	@DRUG$ @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d158.s6.p1	@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d158.s6.p2	@DRUG$ MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d158.s6.p3	MAO inhibitors @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d158.s6.p4	MAO inhibitors @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d158.s6.p5	MAO inhibitors MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d158.s10.p0	@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	DDI-false
DDI-DrugBank.d158.s10.p1	@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	DDI-false
DDI-DrugBank.d158.s10.p2	Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s11.p0	@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	DDI-false
DDI-DrugBank.d158.s11.p1	@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
DDI-DrugBank.d158.s11.p2	Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s12.p0	@DRUG$: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.	DDI-false
DDI-DrugBank.d158.s12.p1	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-false
DDI-DrugBank.d158.s12.p2	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d158.s12.p3	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-effect
DDI-DrugBank.d158.s12.p4	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d158.s12.p5	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d158.s13.p0	@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	DDI-false
DDI-DrugBank.d158.s13.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
DDI-DrugBank.d158.s13.p2	Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
DDI-DrugBank.d158.s14.p0	@DRUG$: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.	DDI-false
DDI-DrugBank.d158.s14.p1	@DRUG$: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
DDI-DrugBank.d158.s14.p2	Haloperidol: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s15.p0	@DRUG$: The anorectic and stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	DDI-false
DDI-DrugBank.d158.s15.p1	@DRUG$: The anorectic and stimulatory effects of amphetamines may be inhibited by @DRUG$.	DDI-false
DDI-DrugBank.d158.s15.p2	Lithium carbonate: The anorectic and stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
DDI-DrugBank.d158.s16.p0	@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	DDI-false
DDI-DrugBank.d158.s16.p1	@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	DDI-false
DDI-DrugBank.d158.s16.p2	Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s17.p0	@DRUG$ therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.	DDI-false
DDI-DrugBank.d158.s17.p1	@DRUG$ therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-false
DDI-DrugBank.d158.s17.p2	Methenamine therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-mechanism
DDI-DrugBank.d158.s18.p0	@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	DDI-false
DDI-DrugBank.d158.s18.p1	@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
DDI-DrugBank.d158.s18.p2	Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s19.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;	DDI-false
DDI-DrugBank.d158.s19.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
DDI-DrugBank.d158.s19.p2	Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
DDI-DrugBank.d158.s21.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	DDI-false
DDI-DrugBank.d158.s21.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
DDI-DrugBank.d158.s21.p2	Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
DDI-DrugBank.d158.s23.p0	@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d158.s23.p1	@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d158.s23.p2	Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-effect
DDI-DrugBank.d158.s24.p0	@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	DDI-false
DDI-DrugBank.d158.s24.p1	@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
DDI-DrugBank.d158.s24.p2	Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
